Global Neuropathic Pain Market
Taille du marché en milliards USD
TCAC :
% 
USD
6.39 Billion
USD
12.93 Billion
2024
2032
 Période de prévision |
2025 –2032 |
 Taille du marché (année de référence) |
USD 6.39 Billion |
 Taille du marché (année de prévision) |
USD 12.93 Billion |
 TCAC |
% |
| Principaux acteurs du marché |
|
Segmentation du marché mondial de la douleur neuropathique, par type (dispositifs de stimulation de la moelle épinière (SCS), stimulation nerveuse périphérique externe, dispositifs de stimulation nerveuse électrique transcutanée (TENS), neuropathie focale, neuropathie automatique et neuropathie proximale), type de produit (rechargeable et non rechargeable), procédure (invasive et non invasive), technologie (stimulation nerveuse électrique transcutanée, stimulation magnétique transcrânienne et stimulation électrique respiratoire), modalité (fixe et portable), mode d'achat (dispositifs en vente libre et sur ordonnance), type de douleur (neuropathie périphérique, neuropathie par compression, neuropathie du membre fantôme, névralgie du trijumeau, névralgie post-herpétique (NPH), neuropathie post-traumatique, douleur au pied et coccydynie), indication (sténose spinale, neuropathie périphérique induite par chimiothérapie, neuropathie diabétique, et autres), diagnostic (imagerie, analyses sanguines et examen physique), traitement (médicaments et thérapie multimodale), utilisateur final (hôpitaux, cliniques, soins à domicile, centres de chirurgie ambulatoire , organismes de recherche et autres), canal de distribution (appel d'offres direct, distributeur tiers et autres) - Tendances et prévisions du secteur jusqu'en 2032
Taille du marché de la douleur neuropathique
- La taille du marché mondial de la douleur neuropathique était évaluée à 6,39 milliards USD en 2024 et devrait atteindre 12,93 milliards USD d'ici 2032 , à un TCAC de 9,20 % au cours de la période de prévision.
- La croissance du marché est largement alimentée par la prévalence croissante de maladies chroniques telles que le diabète, le cancer et la sclérose en plaques, qui sont des causes sous-jacentes majeures de douleurs neuropathiques. L'augmentation de la population gériatrique mondiale contribue également à cette tendance, les personnes âgées étant plus exposées aux lésions nerveuses et aux complications associées.
- Par ailleurs, la demande croissante de traitements efficaces et durables stimule l'innovation pharmaceutique et le développement de thérapies ciblées contre la douleur neuropathique, notamment les antidépresseurs, les anticonvulsivants et les agents topiques. Ces facteurs convergents accélèrent l'adoption de solutions contre la douleur neuropathique, stimulant ainsi considérablement la croissance du secteur.
Analyse du marché de la douleur neuropathique
- Les traitements de la douleur neuropathique, englobant les thérapies pharmacologiques et non pharmacologiques, sont des éléments de plus en plus essentiels de la gestion de la douleur chronique en milieu hospitalier et ambulatoire en raison de leur efficacité à traiter les affections complexes liées aux nerfs, à améliorer la qualité de vie des patients et à réduire les coûts des soins de santé à long terme.
- La demande croissante de traitements contre la douleur neuropathique est principalement alimentée par la prévalence croissante du diabète, du cancer et des troubles neurologiques, ainsi que par le vieillissement de la population mondiale. De plus, une meilleure sensibilisation et l'amélioration des capacités diagnostiques contribuent à une augmentation des taux de traitement et à une intervention plus précoce.
- L'Amérique du Nord a dominé le marché de la douleur neuropathique avec la plus grande part de revenus de 49,33 % en 2024, grâce à une infrastructure de soins de santé bien établie, une forte sensibilisation des patients et des praticiens et une forte présence de sociétés pharmaceutiques clés.
- L'Asie-Pacifique devrait être la région connaissant la croissance la plus rapide sur le marché de la douleur neuropathique au cours de la période de prévision, avec un TCAC projeté de 8,4 %, soutenu par l'augmentation des investissements dans les soins de santé, l'élargissement de l'accès des patients aux thérapies de gestion de la douleur et l'augmentation de l'incidence des maladies chroniques telles que le diabète et les accidents vasculaires cérébraux dans des pays comme l'Inde, la Chine et le Japon.
- Le segment des dispositifs de stimulation de la moelle épinière (SCS) a dominé le marché de la douleur neuropathique par type avec une part de marché de 31,4 % en 2024, en raison de son efficacité dans la gestion des affections douloureuses chroniques qui ne répondent pas aux traitements conventionnels, de sa rentabilité à long terme et de l'adoption croissante de thérapies de neuromodulation mini-invasives.
Portée du rapport et segmentation du marché de la douleur neuropathique
|
Attributs |
Informations clés sur le marché de la douleur neuropathique |
|
Segments couverts |
|
|
Pays couverts |
Amérique du Nord
Europe
Asie-Pacifique
Moyen-Orient et Afrique
Amérique du Sud
|
|
Principaux acteurs du marché |
|
|
Opportunités de marché |
|
|
Ensembles d'informations de données à valeur ajoutée |
Outre les informations sur les scénarios de marché tels que la valeur marchande, le taux de croissance, la segmentation, la couverture géographique et les principaux acteurs, les rapports de marché organisés par Data Bridge Market Research comprennent également une analyse approfondie des experts, une analyse des prix, une analyse de la part de marque, une enquête auprès des consommateurs, une analyse démographique, une analyse de la chaîne d'approvisionnement, une analyse de la chaîne de valeur, un aperçu des matières premières/consommables, des critères de sélection des fournisseurs, une analyse PESTLE, une analyse Porter et un cadre réglementaire. |
Tendances du marché de la douleur neuropathique
« Demande croissante de solutions de traitement intelligentes et intégrées »
- L'intégration de systèmes de traitement intelligents et de solutions thérapeutiques personnalisées est une tendance majeure et croissante sur le marché mondial de la douleur neuropathique. Les avancées des plateformes de santé numérique et des dispositifs médicaux connectés améliorent la prise en charge des patients et optimisent les stratégies de soulagement de la douleur.
- Par exemple, les technologies portables et les appareils connectés sont de plus en plus utilisés pour surveiller les niveaux de douleur et l'observance du traitement, permettant aux prestataires de soins de santé d'effectuer des ajustements de traitement en temps réel pour de meilleurs résultats dans la gestion de la douleur neuropathique.
- De plus, des outils d'analyse de données sont utilisés pour suivre la réponse des patients à des médicaments spécifiques, identifier les facteurs déclenchants et affiner les protocoles de traitement. Certaines plateformes de santé numérique proposent des modèles prédictifs qui anticipent les poussées de douleur en fonction de données comportementales et physiologiques.
- La connexion fluide de ces outils aux dossiers médicaux électroniques (DME) permet aux cliniciens de prendre en charge la douleur neuropathique de manière plus globale. Cette interopérabilité réduit non seulement les erreurs cliniques, mais simplifie également l'optimisation des traitements et le suivi.
- Des entreprises telles que NeuroMetrix sont à la pointe de l'innovation dans ce domaine avec des solutions telles que Quell, un appareil portable pour la douleur chronique qui utilise la stimulation nerveuse et le suivi numérique pour améliorer le soulagement et personnaliser la thérapie.
- Alors que les attentes des patients évoluent vers des soins plus personnalisés, connectés et pratiques, la demande de solutions avancées et intégrées de gestion de la douleur neuropathique augmente dans les milieux hospitaliers et de soins à domicile.
Dynamique du marché de la douleur neuropathique
Conducteur
« Besoin croissant en raison de la prévalence croissante des maladies chroniques et de la demande de solutions efficaces pour la gestion de la douleur »
- La prévalence croissante de maladies chroniques telles que le diabète, le cancer et la sclérose en plaques, principaux contributeurs à la douleur neuropathique, a considérablement alimenté la demande de thérapies ciblées et efficaces pour la gestion de la douleur ces dernières années.
- Par exemple, en mars 2024, Novartis AG a étendu le développement clinique de son composé expérimental LX9211, conçu pour le traitement de la douleur neuropathique périphérique diabétique, soulignant les investissements continus en R&D pour répondre à la demande thérapeutique croissante du marché.
- Face au vieillissement de la population mondiale et à l'aggravation du fardeau des maladies chroniques, les systèmes de santé accordent une importance croissante à l'amélioration de la qualité de vie grâce à des stratégies globales de prise en charge de la douleur. Cela a entraîné une forte augmentation de l'adoption de traitements contre la douleur neuropathique, notamment les anticonvulsivants, les antidépresseurs et de nouvelles thérapies comme les inhibiteurs des canaux sodiques et les agents topiques.
- De plus, l'évolution vers la médecine personnalisée et l'utilisation de biomarqueurs pour adapter les thérapies aux patients individuels renforcent encore l'efficacité du traitement de la douleur neuropathique, améliorant les résultats et la satisfaction des patients.
- La disponibilité croissante d'options thérapeutiques avancées, conjuguée à une sensibilisation accrue des professionnels de santé et des patients, devrait continuer à stimuler une croissance significative du marché mondial de la douleur neuropathique. Les géants pharmaceutiques investissent massivement dans les essais cliniques et l'innovation produit pour répondre à des besoins non satisfaits, notamment dans le soulagement de la douleur non opioïde.
Retenue/Défi
« Effets secondaires des thérapies actuelles et accès limité dans les régions à faible revenu »
- Malgré son potentiel de croissance, le marché des douleurs neuropathiques est confronté à des défis majeurs liés aux effets secondaires des traitements existants. De nombreux médicaments couramment utilisés, tels que les antidépresseurs tricycliques et les gabapentinoïdes, sont connus pour provoquer somnolence, vertiges et troubles gastro-intestinaux, entraînant une mauvaise observance du traitement par les patients.
- Par exemple, plusieurs essais cliniques ont montré que la gabapentine et la prégabaline étaient efficaces dans le traitement des douleurs neuropathiques, mais étaient également associées à des taux d'abandon élevés en raison de problèmes de tolérance. Cela a créé une demande pour des alternatives plus récentes et plus sûres, mais le pipeline clinique tarde encore à produire des innovations révolutionnaires.
- En outre, l'accès aux traitements contre la douleur neuropathique reste limité dans de nombreux pays à revenu faible ou intermédiaire en raison du prix élevé des médicaments, des capacités de diagnostic insuffisantes et du manque de cliniques spécialisées dans le traitement de la douleur.
- Les marchés sensibles aux coûts sont souvent mal desservis, les patients s'appuyant sur des analgésiques en vente libre qui procurent un soulagement minimal de la douleur liée aux nerfs.
- Combler ces lacunes grâce à des programmes d'accès élargi, au développement de génériques rentables et à des partenariats mondiaux en santé sera essentiel pour garantir un accès équitable aux soins. De plus, des campagnes de sensibilisation et des recommandations cliniques sont nécessaires pour aider les médecins à diagnostiquer et à prendre en charge plus efficacement la douleur neuropathique, notamment en médecine générale.
Portée du marché de la douleur neuropathique
Le marché est segmenté sur la base du type, du type de produit, de la procédure, de la technologie, de la modalité, du mode d'achat, du type de douleur, de l'indication, du diagnostic, du traitement, de l'utilisateur final et du canal de distribution.
• Par type
Sur la base du type de dispositif, le marché de la douleur neuropathique est segmenté en dispositifs de stimulation médullaire (SCS), de stimulation nerveuse périphérique externe, de stimulation nerveuse électrique transcutanée (TENS), de neuropathie focale, de neuropathie automatique et de neuropathie proximale. Le segment des dispositifs de stimulation médullaire (SCS) a dominé le marché avec la plus grande part de chiffre d'affaires (31,4 %) en 2024, grâce à la grande efficacité de la SCS dans le soulagement de la douleur neuropathique chronique, en particulier dans les cas résistants aux traitements pharmacologiques. L'augmentation des approbations de la FDA et les avancées technologiques telles que les dispositifs implantables miniaturisés sont également des facteurs contributifs.
Le segment des dispositifs de stimulation nerveuse électrique transcutanée (TENS) devrait connaître le TCAC le plus rapide de 8,9 % entre 2025 et 2032, en raison de la popularité croissante des méthodes non invasives de soulagement de la douleur et de leur utilisation croissante dans les établissements de soins de santé à domicile.
• Par type de produit
En fonction du type de produit, le marché des appareils de traitement de la douleur neuropathique est segmenté en appareils rechargeables et non rechargeables. Le segment rechargeable détenait la plus grande part de marché, soit 58,3 % en 2024, en raison de leur durée de vie plus longue et de leur rentabilité à long terme.
Le segment des produits non rechargeables devrait croître à un TCAC de 6,7 % entre 2025 et 2032, en particulier dans le cadre d'une utilisation thérapeutique à court terme et chez les patients âgés préférant des solutions nécessitant peu d'entretien.
• Par procédure
En fonction des procédures, le marché de la douleur neuropathique est segmenté en procédures invasives et non invasives. Le segment non invasif dominait le marché avec une part de 61,2 % en 2024, les patients privilégiant de plus en plus les thérapies moins douloureuses et nécessitant une éviction sociale minimale.
Le segment invasif devrait croître à un TCAC de 7,5 % entre 2025 et 2032, en raison des progrès des techniques chirurgicales de précision et de l'acceptation croissante des implants de neurostimulation.
• Par technologie
Sur la base de la technologie, le marché de la douleur neuropathique est segmenté en stimulation nerveuse électrique transcutanée (TENS), stimulation magnétique transcrânienne (TMS) et stimulation électrique respiratoire. La technologie de stimulation nerveuse électrique transcutanée (TENS) a dominé le marché avec une part de 45,8 % en 2024, largement utilisée en raison de son prix abordable et de sa facilité d'intégration dans les appareils à usage domestique.
La stimulation magnétique transcrânienne (TMS) devrait enregistrer le TCAC le plus rapide de 9,4 % entre 2025 et 2032, en raison de l'augmentation des essais cliniques démontrant son efficacité pour la dépression liée aux nerfs et les affections neuropathiques.
• Par modalité
En fonction des modalités, le marché de la douleur neuropathique est segmenté en dispositifs fixes et portables. Le segment portable a dominé avec la plus grande part de marché, soit 66,9 % en 2024, grâce à la préférence croissante des patients pour les dispositifs à domicile et à la transition vers des soins décentralisés.
Le segment stationnaire devrait croître à un TCAC de 6,2 % entre 2025 et 2032, restant important dans les hôpitaux et les cliniques spécialisées en raison d'une capacité thérapeutique plus élevée et de paramètres d'application plus larges.
• Par mode d'achat
En fonction du mode d'achat, le marché des douleurs neuropathiques est segmenté en dispositifs en vente libre et dispositifs sur ordonnance. En 2024, les dispositifs sur ordonnance détenaient la part de marché la plus importante, soit 59,1 %, en raison des exigences réglementaires et de leur utilisation dans des thérapies spécialisées.
Les dispositifs en vente libre devraient connaître une croissance annuelle composée (TCAC) rapide de 10,1 % entre 2025 et 2032, alimentée par une sensibilisation croissante des consommateurs à la santé et par l'accès à des outils abordables de gestion de la douleur.
• Par type de douleur
En fonction du type de douleur, le marché des douleurs neuropathiques est segmenté en neuropathies périphériques, neuropathies par compression, neuropathies du membre fantôme, névralgies du trijumeau, névralgies post-herpétiques (NPH), neuropathies post-traumatiques, douleurs aux pieds et coccygodynies. Le segment des neuropathies périphériques dominait avec une part de 39,4 % en 2024, en raison de sa forte prévalence, notamment chez les patients diabétiques.
Le segment des névralgies post-herpétiques (NPH) devrait croître à un TCAC de 8,6 % entre 2025 et 2032, en raison de l’incidence croissante des infections à zona parmi la population vieillissante.
• Par indication
Sur la base des indications, le marché des douleurs neuropathiques est segmenté en sténose spinale, neuropathie périphérique induite par la chimiothérapie (PNIC), neuropathie diabétique et autres. La neuropathie diabétique représentait la plus grande part de chiffre d'affaires, soit 42,7 % en 2024, grâce à la hausse mondiale de la prévalence du diabète.
La neuropathie périphérique induite par la chimiothérapie (PNIC) devrait connaître la croissance la plus rapide avec un TCAC de 9,2 % entre 2025 et 2032, en raison du nombre croissant de survivants du cancer recherchant un soulagement de la douleur à long terme.
• Par diagnostic
Sur la base du diagnostic, le marché de la douleur neuropathique est segmenté en imagerie, analyses sanguines et examen physique. Le segment de l'imagerie était en tête du marché avec une part de marché de 48,5 % en 2024, avec une adoption croissante de l'IRM et du scanner pour détecter les lésions nerveuses.
Le segment des examens physiques devrait croître à un TCAC de 6,9 % entre 2025 et 2032, en raison de sa disponibilité et de son utilisation généralisées dans les soins primaires.
• Par traitement
En fonction du traitement, le marché de la douleur neuropathique est segmenté en médicaments et en thérapies multimodales. Les médicaments dominaient le marché avec une part de 64,8 % en 2024, grâce à la large disponibilité des analgésiques, des anticonvulsivants et des antidépresseurs.
La thérapie multimodale devrait connaître une croissance TCAC rapide de 10,5 % entre 2025 et 2032, car les prestataires de soins de santé recommandent de plus en plus des approches intégratives combinant des traitements physiques, pharmacologiques et cognitifs.
• Par l'utilisateur final
En fonction de l'utilisateur final, le marché de la douleur neuropathique est segmenté en hôpitaux, cliniques, soins à domicile, centres de chirurgie ambulatoire, organismes de recherche, etc. Le segment hospitalier représentait la part de marché la plus élevée, soit 49,34 % en 2024, grâce à la disponibilité de soins spécialisés et de dispositifs thérapeutiques avancés.
Le segment des soins de santé à domicile devrait connaître le TCAC le plus rapide, soit 9,8 %, entre 2025 et 2032, en raison de l'augmentation du nombre de patients souffrant de douleurs chroniques préférant les thérapies à domicile.
• Par canal de distribution
En fonction du canal de distribution, le marché des douleurs neuropathiques est segmenté en appels d'offres directs, distributeurs tiers et autres. Le segment des appels d'offres directs dominait avec une part de marché de 52,4 % en 2024, principalement grâce aux achats groupés des hôpitaux et des systèmes de santé publique.
Le segment des distributeurs tiers devrait connaître le TCAC le plus rapide de 8,7 % entre 2025 et 2032, en raison de l'expansion des établissements de santé privés et de la pénétration des appareils dans les économies émergentes.
Analyse régionale du marché de la douleur neuropathique
- L'Amérique du Nord a dominé le marché de la douleur neuropathique avec la plus grande part de revenus de 49,33 % en 2024, en raison de la prévalence croissante de maladies chroniques telles que le diabète et le cancer, qui sont les principales causes sous-jacentes de la douleur neuropathique.
- Les patients de la région recherchent de plus en plus des thérapies avancées de gestion de la douleur, notamment des dispositifs de neurostimulation et des traitements multimodaux, soutenus par une infrastructure de soins de santé robuste et une disponibilité généralisée de thérapies remboursables.
- La croissance du marché est également soutenue par de forts investissements en R&D, des niveaux élevés de sensibilisation au diagnostic et au traitement précoces et la présence d'acteurs clés du marché proposant des appareils technologiquement avancés, faisant de l'Amérique du Nord une plaque tournante pour l'innovation et l'adoption de traitements contre la douleur neuropathique.
Aperçu du marché américain de la douleur neuropathique
Le marché américain de la douleur neuropathique a représenté la plus grande part de chiffre d'affaires en 2024. Cette domination est alimentée par l'adoption généralisée de thérapies avancées telles que les dispositifs de neuromodulation et les protocoles de traitement multimodaux. Cette croissance est soutenue par des technologies de diagnostic accessibles, des dépenses de santé élevées et de solides investissements en R&D.
Aperçu du marché européen de la douleur neuropathique
Le marché européen des douleurs neuropathiques devrait connaître une croissance annuelle moyenne (TCAC) substantielle sur la période de prévision 2025-2032. Cette croissance est principalement due à des réglementations de sécurité strictes et au besoin croissant de renforcement de la sécurité au domicile et au travail. La région devrait connaître une croissance annuelle moyenne (TCAC) soutenue, portée par l'incidence croissante des neuropathies diabétiques et cancéreuses et par l'adoption généralisée de traitements non invasifs tels que la TENS et la TMS.
Aperçu du marché de la douleur neuropathique en Asie-Pacifique
Le marché de la douleur neuropathique en Asie-Pacifique devrait connaître le TCAC le plus rapide de 8,4 % entre 2025 et 2032. La croissance est tirée par l'expansion des infrastructures de soins de santé, l'augmentation de la prévalence des maladies chroniques et l'adoption de thérapies rentables dans des pays comme la Chine et l'Inde.
Aperçu du marché japonais de la douleur neuropathique
Le marché japonais de la douleur neuropathique devrait croître à un TCAC de 6,2 % entre 2025 et 2032. Cette croissance est soutenue par le vieillissement de sa population, ses systèmes de santé avancés et une adoption accrue de dispositifs de gestion de la douleur portables et implantables.
Aperçu du marché chinois de la douleur neuropathique
Le marché chinois de la douleur neuropathique représentait la plus grande part de revenus du marché en 2024. Cette croissance est propulsée par une forte production nationale, des investissements publics et une charge élevée de maladies chroniques.
Part de marché de la douleur neuropathique
L'industrie de la douleur neuropathique est principalement dirigée par des entreprises bien établies, notamment :
- NEVRO CORP. (États-Unis)
- Lilly (États-Unis)
- Astellas Pharma Inc. (Japon)
- Biogen (États-Unis)
- Cirtec (États-Unis)
- Integer Holdings Corporation (États-Unis)
- B. Braun SE (Allemagne)
- Medtronic (Irlande)
- Abbott (États-Unis)
- Boston Scientific Corporation (États-Unis)
- OMRON Healthcare Co., Ltd. (Japon)
- electroCore, Inc. (États-Unis)
- Polar Medical Ltd (Royaume-Uni)
- SunMED Medical (États-Unis)
- NeuroMetrix, Inc. (États-Unis)
Derniers développements sur le marché mondial de la douleur neuropathique
- En avril 2025, des chercheurs de Virginia Tech ont démontré que l'échographie focalisée transspinale non invasive (tsFUS) pouvait réduire significativement la sensibilité à la douleur et la neuroinflammation dans des modèles de lésions médullaires. Ces courtes séances de 3 minutes, réparties sur 3 jours, ont procuré un soulagement pendant plusieurs semaines sans recours à des médicaments ni à la chirurgie, ouvrant ainsi une voie prometteuse pour la prise en charge non pharmacologique de la douleur.
- En mars 2025, la revue The Lancet Neurology a publié des recommandations cliniques mondiales actualisées pour le traitement des douleurs neuropathiques, réaffirmant l'utilisation des ligands α2δ (prégabaline, gabapentine), des IRSN (duloxétine) et des antidépresseurs tricycliques (amitriptyline) comme traitements de première intention. Elle a également souligné l'efficacité limitée des opioïdes et la nécessité de stratégies thérapeutiques multimodales.
- En janvier 2025, la FDA a approuvé la suzétrigine (Journavx) de Vertex Pharmaceuticals, premier analgésique non opioïde depuis plus de 20 ans pour le traitement de la douleur aiguë. Bien qu'elle cible principalement la douleur postopératoire aiguë, des études complémentaires sont en cours pour évaluer son potentiel dans le traitement des maladies neuropathiques chroniques.
- En février 2025, Haisco Pharmaceutical Group a étendu son développement clinique de la Crisugabaline (HSK16149), un analogue du GABA de nouvelle génération, aux États-Unis et en Europe après avoir obtenu l'approbation réglementaire en Chine pour la neuropathie diabétique et la névralgie post-herpétique en 2024.
- En mars 2025, des chercheurs de l'UNSW Sydney ont lancé PainWaive, une application numérique de neurofeedback associée à un casque de lecture cérébrale conçu pour aider les patients à autoréguler l'activité cérébrale associée à la douleur chronique. Les premières études ont montré une amélioration de la qualité de vie et de la perception de la douleur, laissant entrevoir un avenir pour les thérapies à domicile sans médicaments.
- En juin 2025, le 9e Congrès international sur la douleur neuropathique (NeuPSIG 2025) à Berlin devrait présenter des avancées majeures en matière de neuromodulation, de diagnostics basés sur l'IA et de thérapies non opioïdes, renforçant ainsi l'évolution croissante vers une gestion de la douleur personnalisée et axée sur la technologie.
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
- INTRODUCTION
- OBJECTIVES OF THE STUDY
- MARKET DEFINITION
- OVERVIEW OF GLOBAL NEUROPATHIC PAIN MARKET
- LIMITATIONS
- MARKETS COVERED
- MARKET SEGMENTATION
- MARKETS COVERED
- GEOGRAPHICAL SCOPE
- YEARS CONSIDERED FOR THE STUDY
- CURRENCY AND PRICING
- DBMR TRIPOD DATA VALIDATION MODEL
- MULTIVARIATE MODELLING
- TYPE LIFELINE CURVE
- PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
- DBMR MARKET POSITION GRID
- VENDOR SHARE ANALYSIS
- MARKET TYPE OF MANUFACTURER COVERAGE GRID
- SECONDARY SOURCES
- ASSUMPTIONS
- EXECUTIVE SUMMARY
- PREMIUM INSIGHT
- REGULATION
- REGULATORY GUIDELINES AS PER USFDA
- REGULATORY GUIDELINES AS PER EUROPEAN UNION
- MARKET OVERVIEW
- DRIVERS
- GROWING PREVALENCE OF CHRONIC PAIN AND NEUROPATHIC CONDITION
- INCREASING CASES OF DIABETIC NEUROPATHY
- INCREASING R&D EXPENDITURE
- ADVANCEMENT IN NEW NEUROMODULATION TECHNOLOGY
- PENETRATION OF THE NEW MARKET PLAYERS
- RESTRAINTS
- HIGH COST OF THE MEDICAL DEVICES
- LOW AWARENESS FOR NEUROPATHIC PAIN DEVICES
- UNFAVORABLE GOVERNMENT POLICIES
- LIMITATION OF NEUROPATHIC MEDICAL DEVICES
- OPPORTUNITIES
- HIGH RISK OF NEUROPATHIC PAIN WITH AGEING
- GOVERNMENT INITIATIVES FOR NEUROPATHIC PAIN
- APPROPRIATE REIMBURSEMENT POLICY FOR THE MEDICAL DEVICES
- CHALLENGES
- DEARTH OF SKILLED PROFESSIONALS
- USE OF TRADITIONAL THERAPY IN EMERGING ECONOMIES
- IMPACT OF COVID-19 ON THE GLOBAL NEUROPATHIC PAIN MARKET
- OVERVIEW
- IMPACT ON PRICE
- IMPACT ON SUPPLY
- STRATEGIC DECISIONS BY MANUFACTURERS
- CONCLUSION-
- GLOBAL NEUROPATHIC PAIN MARKET, BY TYPE
- OVERVIEW
- SPINAL CORD STIMULATION (SCS) DEVICES
- RECHARGEABLE IMPLANTABLE PULSE GENERATOR
- RADIOFREQUENCY STIMULATOR
- CONVENTIONAL IMPLANTABLE PULSE GENERATOR/ IPG
- EXTERNAL PERIPHERAL NERVE STIMULATION
- DEEP BRAIN STIMULATORS (DBS)
- DUAL-CHANNEL DEEP BRAIN STIMULATOR
- SINGLE-CHANNEL DEEP BRAIN STIMULATOR
- TRANSCRANIAL MAGNETIC STIMULATORS (TMS)
- VAGUS NERVE STIMULATORS (VNS)
- SACRAL NERVE STIMULATORS (SNS)
- TRANSCUTANEOUS ELECTRIC NERVE STIMULATION (TENS) DEVICES
- CONVENTIONAL TENS (LOW-INTENSITY, HIGH-FREQUENCY)
- ACUPUNCTURE-LIKE TENS (HIGH-INTENSITY, LOW-FREQUENCY)
- INTENSE TENS (HIGH-INTENSITY, HIGH-FREQUENCY)
- GLOBAL NEUROPATHIC PAIN MARKET, BY PRODUCT TYPE
- OVERVIEW
- RECHARGEABLE
- NON- RECHARGEABLE
- GLOBAL NEUROPATHIC PAIN MARKET, BY PROCEDURE
- OVERVIEW
- NON-INVASIVE
- INVASIVE
- GLOBAL NEUROPATHIC PAIN MARKET, BY TECHNOLOGY
- OVERVIEW
- TRANSCUTANEOUS ELECTRIC NERVE STIMULATION
- TRANSCRANIAL MAGNETIC STIMULATION
- RESPIRATORY ELECTRICAL STIMULATION
- GLOBAL NEUROPATHIC PAIN MARKET, BY MODALITY
- OVERVIEW
- PORTABLE
- RECHARGEABLE
- NON- RECHARGEABLE
- STATIONARY
- RECHARGEABLE
- NON- RECHARGEABLE
- GLOBAL NEUROPATHIC PAIN MARKET, BY MODE OF PURCHASE
- OVERVIEW
- PRESCRIPTION-BASED DEVICES
- OVER-THE-COUNTER DEVICES
- GLOBAL NEUROPATHIC PAIN MARKET, BY PAIN TYPE
- OVERVIEW
- PERIPHERAL NEUROPATHY
- PHANTOM LIMB PAIN
- POST HERPETIC NEURALGIA (PHN)
- POST TRAUMATIC NEUROPATHY
- ENTRAPMENT NEUROPATHY
- FOOT PAIN
- TRIGEMINAL NEURALGIA
- COCCYDYNIA
- OTHERS
- GLOBAL NEUROPATHIC PAIN MARKET, BY INDICATION
- OVERVIEW
- SPINAL STENOSIS
- SPINAL CORD STIMULATION (SCS) DEVICES
- TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION (TENS) DEVICES
- EXTERNAL PERIPHERAL NERVE STIMULATION
- DIABETIC NEUROPATHY
- SPINAL CORD STIMULATION (SCS) DEVICES
- TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION (TENS) DEVICES
- EXTERNAL PERIPHERAL NERVE STIMULATION
- CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY
- SPINAL CORD STIMULATION (SCS) DEVICES
- TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION (TENS) DEVICES
- EXTERNAL PERIPHERAL NERVE STIMULATION
- OTHERS
- GLOBAL NEUROPATHIC PAIN MARKET, BY END USER
- OVERVIEW
- CLINICS
- HOSPITALS
- ACUTE CARE HOSPITALS
- LONG-TERM CARE HOSPITALS
- NURSING FACILITIES
- REHABILITATION CENTERS
- HOME HEALTHCARE
- AMBULATORY SURGICAL CENTERS
- OTHERS
- GLOBAL NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL
- OVERVIEW
- DIRECT TENDERS
- THIRD PARTY DISTRIBUTION
- OTHERS
- GLOBAL NEUROPATHIC PAIN MARKET BY GEOGRAPHY
- OVERVIEW
- NORTH-AMERICA
- U.S.
- CANADA
- MEXICO
- EUROPE
- GERMANY
- FRANCE
- U.K.
- ITALY
- RUSSIA
- SPAIN
- NETHERLANDS
- TURKEY
- SWITZERLAND
- REST OF EUROPE
- ASIA-PACIFIC
- CHINA
- JAPAN
- AUSTRALIA
- INDIA
- SOUTH KOREA
- SINGAPORE
- MALAYSIA
- THAILAND
- INDONESIA
- PHILIPPINES
- REST OF ASIA-PACIFIC
- MIDDLE EAST AND AFRICA
- SOUTH AFRICA
- SAUDI ARABIA
- UAE
- ISRAEL
- EGYPT
- REST OF MIDDLE EAST & AFRICA
- SOUTH AMERICA
- BRAZIL
- ARGENTINA
- REST OF SOUTH AMERICA
- GLOBAL NEUROPATHIC PAIN MARKET: COMPANY LANDSCAPE
- COMPANY SHARE ANALYSIS: GLOBAL
- COMPANY SHARE ANALYSIS: NORTH AMERICA
- COMPANY SHARE ANALYSIS: EUROPE
- COMPANY SHARE ANALYSIS: ASIA-PACIFIC
- SWOT ANALYSIS
- COMPANY PROFILE
- MEDTRONIC
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- COMPANY SHARE ANALYSIS
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- BOSTON SCIENTIFIC CORPORATION
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- COMPANY SHARE ANALYSIS
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- ABBOTT
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- COMPANY SHARE ANALYSIS
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENT
- NERVO CORP.
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- COMPANY SHARE ANALYSIS
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- OMRON HEALTHCARE, INC.
- COMPANY SNAPSHOT
- COMPANY SHARE ANALYSIS
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- INTERGER HOLDINGS CORPORATION
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- AVNS
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- B.BRAUN MELSUNGEN AG
- COMPANY SNAPSHOT
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENT
- CIRTEC
- 428
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- ELECTROCORE, INC.
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- NEUROMETRIX, INC.
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- POLAR MEDICAL
- COMPANY SNAPSHOT
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENT
- SPR THERAPEUTICS
- COMPANY SNAPSHOT
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- STIMWAVE LLC.
- COMPANY SNAPSHOT
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENT
- SUNMED
- COMPANY SNAPSHOT
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENT
- QUESTIONNAIRE
- RELATED REPORTS
Liste des tableaux
TABLE 1 Global Neuropathic Pain Market, By Type, 2019-2028 (USD Million)
TABLE 2 Global Spinal Cord Stimulation (SCS) Devices in Neuropathic Pain Market, By Type, 2019-2028 (USD Million)
TABLE 3 Global Spinal Cord Stimulation (SCS) Devices in Neuropathic Pain Market, By Type, 2019-2028 (USD Million)
TABLE 4 Global External Peripheral Nerve Stimulationin Neuropathic Pain Market, By Type, 2019-2028 (USD Million)
TABLE 5 Global External Peripheral Nerve Stimulationin Neuropathic Pain Market, By Type, 2019-2028 (USD Million)
TABLE 6 Global Deep Brain Stimulators (DBS) in Neuropathic Pain Market, By Type, 2019-2028 (USD Million)
TABLE 7 Global Transcutaneous Electrical Nerve Stimulation (TENS) Devices in Neuropathic Pain Market, By Type, 2019-2028 (USD Million)
TABLE 8 Global Transcutaneous Electrical Nerve Stimulation (TENS) Devices in Neuropathic Pain Market, By Type, 2019-2028 (USD Million)
TABLE 9 Global Neuropathic Pain Market, By Product Type, 2019-2028 (USD Million)
TABLE 10 Global Rechargeable in Neuropathic Pain Market, By Product Type, 2019-2028 (USD Million)
TABLE 11 Global Non-Rechargeable Neuropathic Pain Market, By Product Type, 2019-2028 (USD Million)
TABLE 12 Global Neuropathic Pain Device Market, By Procedure, 2019-2028 (USD Million)
TABLE 13 Global Non-Invasive Invasive in Neuropathic Pain Device Market, By Procedure, 2019-2028 (USD Million)
TABLE 14 Global Invasive in Neuroendocrine Tumors Market, By Classification 2019-2027 (USD Million)
TABLE 15 Global Neuropathic Pain Market, By Technology, 2019-2028 (USD Million)
TABLE 16 Global Transcutaneous Electrical Nerve Stimulation Neuropathic Pain Market, By Technology, 2019-2028 (USD Million)
TABLE 17 Global Transcranial Magnetic Stimulation Neuropathic Pain Market, By Technology, 2019-2028 (USD Million)
TABLE 18 Global Respiratory Electrical Stimulation Neuropathic Pain Market, By Technology, 2019-2028 (USD Million)
TABLE 19 Global Neuropathic Pain Market, By Modality, 2019-2028 (USD Million)
TABLE 20 Global Portable Neuropathic Pain Market, By Modality, 2019-2028 (USD Million)
TABLE 21 Global Portable in Neuropathic Pain Market, By Modality, 2019-2028 (USD Million)
TABLE 22 Global Stationary Neuropathic Pain Market, By Modality, 2019-2028 (USD Million)
TABLE 23 Global Stationary Neuropathic Pain Market, By Modality, 2019-2028 (USD Million)
TABLE 24 Global Neuropathic Pain Market, By Mode of Purchase, 2019-2028 (USD Million)
TABLE 25 Global Prescription-Based Devices Neuropathic Pain Market, By Mode of Purchase, 2019-2028 (USD Million)
TABLE 26 Global Over-The-Counter Devices Neuropathic Pain Market, By Mode of Purchase, 2019-2028 (USD Million)
TABLE 27 Global Neuropathic Pain Market, By Pain Type, 2019-2028 (USD Million)
TABLE 28 Global Peripheral Neuropathy Neuropathic Pain Market, By Pain Type, 2019-2028 (USD Million)
TABLE 29 Global Phantom Limb Pain Neuropathic Pain Market, By Pain Type, 2019-2028 (USD Million)
TABLE 30 Global Post Herpetic Neuralgia (PHN) Neuropathic Pain Market, By Pain Type, 2019-2028 (USD Million)
TABLE 31 Global Post Traumatic NeuropathyNeuropathic Pain Market, By Pain Type, 2019-2028 (USD Million)
TABLE 32 Global Entrapment Neuropathy Neuropathic Pain Market, By Pain Type, 2019-2028 (USD Million)
TABLE 33 Global Foot Pain Neuropathic Pain Market, By Pain Type, 2019-2028 (USD Million)
TABLE 34 Global Trigeminal Neuralgia Neuropathic Pain Market, By Pain Type, 2019-2028 (USD Million)
TABLE 35 Global Coccydynia Neuropathic Pain Market, By Pain Type, 2019-2028 (USD Million)
TABLE 36 Global Others Neuropathic Pain Market, By Pain Type, 2019-2028 (USD Million)
TABLE 37 Global Neuropathic Pain Market, By Indication, 2019-2028 (USD Million)
TABLE 38 Global Spinal Stenosis Neuropathic Pain Market, By Indication, 2019-2028 (USD Million)
TABLE 39 Global Spinal Stenosis in Neuropathic Pain Market, By Indication, 2019-2028 (USD Million)
TABLE 40 Global Diabetic Neuropathy Neuropathic Pain Market, By Indication, 2019-2028 (USD Million)
TABLE 41 Global Diabetic Neuropathy in Neuropathic Pain Market, By Indication, 2019-2028 (USD Million)
TABLE 42 Global Chemotherapy-Induced Peripheral Neuropathy Neuropathic Pain Market, By Indication, 2019-2028 (USD Million)
TABLE 43 Global Chemotherapy-Induced Peripheral Neuropathy in Neuropathic Pain Market, By Indication, 2019-2028 (USD Million)
TABLE 44 Global Others Neuropathic Pain Market, By Indication, 2019-2028 (USD Million)
TABLE 45 Global Neuropathic Pain Market, By End User, 2019-2028 (USD Million)
TABLE 46 Global Clinics Neuropathic Pain Market, By End User, 2019-2028 (USD Million)
TABLE 47 Global Hospitals Neuropathic Pain Market, By End User, 2019-2028 (USD Million)
TABLE 48 Global Hospitals in Neuropathic Pain Market, By End User, 2019-2028 (USD Million)
TABLE 49 Global Home Healthcare Neuropathic Pain Market, By End User, 2019-2028 (USD Million)
TABLE 50 Global Ambulatory Surgical Centers Neuropathic Pain Market, By End User, 2019-2028 (USD Million)
TABLE 51 Global Others Neuropathic Pain Market, By End User, 2019-2028 (USD Million)
TABLE 52 Global Neuropathic Pain Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 53 Global Direct Tenders Neuropathic Pain Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 54 Global Third Party Distribution Neuropathic Pain Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 55 Global Others Neuropathic Pain Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 56 GLOBAL neuropathic Pain MARKET, BY REGION , 2021-2028 (USD MILLION)
TABLE 57 North-america NEUROPATHIC PAIN MARKET, By Region, 2019-2028 (USD Million)
TABLE 58 NORTH-AMERICA NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 59 NORTH-AMERICA Spinal Cord Stimulation (SCS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 60 NORTH-AMERICA External Peripheral Nerve Stimulation in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 61 NORTH-AMERICA Deep Brain Stimulators (DBS) in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 62 NORTH-AMERICA Transcutaneous Electrical Nerve Stimulation (TENS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 63 NORTH-AMERICA NEUROPATHIC PAIN MARKET, By PRODUCT TYPE, 2019-2028 (USD Million)
TABLE 64 NORTH-AMERICA NEUROPATHIC PAIN MARKET, By PROcedure, 2019-2028 (USD Million)
TABLE 65 NORTH-AMERICA NEUROPATHIC PAIN MARKET, By technology, 2019-2028 (USD Million)
TABLE 66 NORTH-AMERICA NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 67 NORTH-AMERICA Stationary in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 68 NORTH-AMERICA portable in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 69 NORTH-AMERICA NEUROPATHIC PAIN MARKET, By Mode of purchase, 2019-2028 (USD Million)
TABLE 70 NORTH-AMERICA NEUROPATHIC PAIN MARKET, By pain type, 2019-2028 (USD Million)
TABLE 71 NORTH-AMERICA NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 72 NORTH-AMERICA SPINAL STENOSIS IN NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 73 NORTH-AMERICA Chemotherapy-Induced Peripheral Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 74 NORTH-AMERICA Diabetic Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 75 NORTH-AMERICA NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)
TABLE 76 NORTH-AMERICA hospitals in NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)
TABLE 77 NORTH-AMERICA NEUROPATHIC PAIN MARKET, By distribution channel, 2019-2028 (USD Million)
TABLE 78 U.S. NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 79 U.S. Spinal Cord Stimulation (SCS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 80 U.S. External Peripheral Nerve Stimulation in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 81 NORTH-AMERICA Deep Brain Stimulators (DBS) in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 82 U.S. Transcutaneous Electrical Nerve Stimulation (TENS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 83 U.S. NEUROPATHIC PAIN MARKET, By PRODUCT TYPE, 2019-2028 (USD Million)
TABLE 84 U.S. NEUROPATHIC PAIN MARKET, By PROcedure, 2019-2028 (USD Million)
TABLE 85 U.S. NEUROPATHIC PAIN MARKET, By technology, 2019-2028 (USD Million)
TABLE 86 U.S. NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 87 U.S. Stationary in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 88 U.S. portable in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 89 U.S. NEUROPATHIC PAIN MARKET, By Mode of purchase, 2019-2028 (USD Million)
TABLE 90 U.S. NEUROPATHIC PAIN MARKET, By pain type, 2019-2028 (USD Million)
TABLE 91 U.S. NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 92 U.S. SPINAL STENOSIS IN NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 93 U.S. Chemotherapy-Induced Peripheral Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 94 U.S. Diabetic Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 95 U.S. NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)
TABLE 96 U.S. hospitals in NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)
TABLE 97 U.S. NEUROPATHIC PAIN MARKET, By distribution channel, 2019-2028 (USD Million)
TABLE 98 canada NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 99 canada Spinal Cord Stimulation (SCS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 100 canada External Peripheral Nerve Stimulation in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 101 canada Deep Brain Stimulators (DBS) in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 102 canada Transcutaneous Electrical Nerve Stimulation (TENS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 103 canada NEUROPATHIC PAIN MARKET, By PRODUCT TYPE, 2019-2028 (USD Million)
TABLE 104 canada NEUROPATHIC PAIN MARKET, By PROcedure, 2019-2028 (USD Million)
TABLE 105 canada NEUROPATHIC PAIN MARKET, By technology, 2019-2028 (USD Million)
TABLE 106 canada NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 107 canada Stationary in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 108 canada portable in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 109 canada NEUROPATHIC PAIN MARKET, By Mode of purchase, 2019-2028 (USD Million)
TABLE 110 canada NEUROPATHIC PAIN MARKET, By pain type, 2019-2028 (USD Million)
TABLE 111 canada NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 112 canada SPINAL STENOSIS IN NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 113 canada Chemotherapy-Induced Peripheral Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 114 canada Diabetic Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 115 canada NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)
TABLE 116 canada hospitals in NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)
TABLE 117 canada NEUROPATHIC PAIN MARKET, By distribution channel, 2019-2028 (USD Million)
TABLE 118 mexico NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 119 mexico Spinal Cord Stimulation (SCS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 120 mexico External Peripheral Nerve Stimulation in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 121 mexico Deep Brain Stimulators (DBS) in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 122 mexico Transcutaneous Electrical Nerve Stimulation (TENS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 123 mexico NEUROPATHIC PAIN MARKET, By PRODUCT TYPE, 2019-2028 (USD Million)
TABLE 124 mexico NEUROPATHIC PAIN MARKET, By PROcedure, 2019-2028 (USD Million)
TABLE 125 mexico NEUROPATHIC PAIN MARKET, By technology, 2019-2028 (USD Million)
TABLE 126 mexico NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 127 mexico Stationary in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 128 mexico portable in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 129 mexico NEUROPATHIC PAIN MARKET, By Mode of purchase, 2019-2028 (USD Million)
TABLE 130 mexico NEUROPATHIC PAIN MARKET, By pain type, 2019-2028 (USD Million)
TABLE 131 mexico NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 132 mexico SPINAL STENOSIS IN NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 133 mexico Chemotherapy-Induced Peripheral Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 134 mexico Diabetic Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 135 mexico NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)
TABLE 136 mexico hospitals in NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)
TABLE 137 mexico NEUROPATHIC PAIN MARKET, By distribution channel, 2019-2028 (USD Million)
TABLE 138 Europe NEUROPATHIC PAIN MARKET, By Region, 2019-2028 (USD Million)
TABLE 139 EUROPE NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 140 EUROPE Spinal Cord Stimulation (SCS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 141 EUROPE External Peripheral Nerve Stimulation in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 142 EUROPE Deep Brain Stimulators (DBS) in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 143 EUROPE Transcutaneous Electrical Nerve Stimulation (TENS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 144 EUROPE NEUROPATHIC PAIN MARKET, By PRODUCT TYPE, 2019-2028 (USD Million)
TABLE 145 EUROPE NEUROPATHIC PAIN MARKET, By PROcedure, 2019-2028 (USD Million)
TABLE 146 EUROPE NEUROPATHIC PAIN MARKET, By technology, 2019-2028 (USD Million)
TABLE 147 EUROPE NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 148 EUROPE Stationary in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 149 EUROPE portable in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 150 EUROPE NEUROPATHIC PAIN MARKET, By Mode of purchase, 2019-2028 (USD Million)
TABLE 151 EUROPE NEUROPATHIC PAIN MARKET, By pain type, 2019-2028 (USD Million)
TABLE 152 EUROPE NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 153 EUROPE SPINAL STENOSIS IN NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 154 EUROPE Chemotherapy-Induced Peripheral Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 155 EUROPE Diabetic Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 156 EUROPE NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)
TABLE 157 EUROPE hospitals in NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)
TABLE 158 EUROPE NEUROPATHIC PAIN MARKET, By distribution channel, 2019-2028 (USD Million)
TABLE 159 GERMANY NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 160 GERMANY Spinal Cord Stimulation (SCS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 161 GERMANY External Peripheral Nerve Stimulation in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 162 germany Deep Brain Stimulators (DBS) in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 163 GERMANY Transcutaneous Electrical Nerve Stimulation (TENS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 164 GERMANY NEUROPATHIC PAIN MARKET, By PRODUCT TYPE, 2019-2028 (USD Million)
TABLE 165 GERMANY NEUROPATHIC PAIN MARKET, By PROcedure, 2019-2028 (USD Million)
TABLE 166 GERMANY NEUROPATHIC PAIN MARKET, By technology, 2019-2028 (USD Million)
TABLE 167 GERMANY NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 168 GERMANY Stationary in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 169 GERMANY portable in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 170 GERMANY NEUROPATHIC PAIN MARKET, By Mode of purchase, 2019-2028 (USD Million)
TABLE 171 GERMANY NEUROPATHIC PAIN MARKET, By pain type, 2019-2028 (USD Million)
TABLE 172 GERMANY NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 173 GERMANY SPINAL STENOSIS IN NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 174 GERMANY Chemotherapy-Induced Peripheral Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 175 GERMANY Diabetic Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 176 GERMANY NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)
TABLE 177 GERMANY hospitals in NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)
TABLE 178 GERMANY NEUROPATHIC PAIN MARKET, By distribution channel, 2019-2028 (USD Million)
TABLE 179 france NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 180 france Spinal Cord Stimulation (SCS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 181 france External Peripheral Nerve Stimulation in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 182 france Deep Brain Stimulators (DBS) in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 183 france Transcutaneous Electrical Nerve Stimulation (TENS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 184 france NEUROPATHIC PAIN MARKET, By PRODUCT TYPE, 2019-2028 (USD Million)
TABLE 185 france NEUROPATHIC PAIN MARKET, By PROcedure, 2019-2028 (USD Million)
TABLE 186 france NEUROPATHIC PAIN MARKET, By technology, 2019-2028 (USD Million)
TABLE 187 france NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 188 france Stationary in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 189 france portable in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 190 france NEUROPATHIC PAIN MARKET, By Mode of purchase, 2019-2028 (USD Million)
TABLE 191 france NEUROPATHIC PAIN MARKET, By pain type, 2019-2028 (USD Million)
TABLE 192 france NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 193 france SPINAL STENOSIS IN NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 194 france Chemotherapy-Induced Peripheral Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 195 france Diabetic Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 196 france NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)
TABLE 197 france hospitals in NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)
TABLE 198 france NEUROPATHIC PAIN MARKET, By distribution channel, 2019-2028 (USD Million)
TABLE 199 U.K. NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 200 U.K. Spinal Cord Stimulation (SCS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 201 U.K. External Peripheral Nerve Stimulation in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 202 U.K. Deep Brain Stimulators (DBS) in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 203 U.K. Transcutaneous Electrical Nerve Stimulation (TENS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 204 U.K. NEUROPATHIC PAIN MARKET, By PRODUCT TYPE, 2019-2028 (USD Million)
TABLE 205 U.K. NEUROPATHIC PAIN MARKET, By PROcedure, 2019-2028 (USD Million)
TABLE 206 U.K. NEUROPATHIC PAIN MARKET, By technology, 2019-2028 (USD Million)
TABLE 207 U.K. NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 208 U.K. Stationary in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 209 U.K. portable in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 210 U.K. NEUROPATHIC PAIN MARKET, By Mode of purchase, 2019-2028 (USD Million)
TABLE 211 U.K. NEUROPATHIC PAIN MARKET, By pain type, 2019-2028 (USD Million)
TABLE 212 U.K. NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 213 U.K. SPINAL STENOSIS IN NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 214 U.K. Chemotherapy-Induced Peripheral Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 215 U.K. Diabetic Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 216 U.K. NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)
TABLE 217 U.K. hospitals in NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)
TABLE 218 U.K. NEUROPATHIC PAIN MARKET, By distribution channel, 2019-2028 (USD Million)
TABLE 219 italy NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 220 italy Spinal Cord Stimulation (SCS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 221 italy External Peripheral Nerve Stimulation in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 222 italy Deep Brain Stimulators (DBS) in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 223 italy Transcutaneous Electrical Nerve Stimulation (TENS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 224 italy NEUROPATHIC PAIN MARKET, By PRODUCT TYPE, 2019-2028 (USD Million)
TABLE 225 italy NEUROPATHIC PAIN MARKET, By PROcedure, 2019-2028 (USD Million)
TABLE 226 italy NEUROPATHIC PAIN MARKET, By technology, 2019-2028 (USD Million)
TABLE 227 italy NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 228 italy Stationary in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 229 italy portable in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 230 italy NEUROPATHIC PAIN MARKET, By Mode of purchase, 2019-2028 (USD Million)
TABLE 231 italy NEUROPATHIC PAIN MARKET, By pain type, 2019-2028 (USD Million)
TABLE 232 italy NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 233 italy SPINAL STENOSIS IN NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 234 italy Chemotherapy-Induced Peripheral Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 235 italy Diabetic Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 236 italy NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)
TABLE 237 italy hospitals in NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)
TABLE 238 italy NEUROPATHIC PAIN MARKET, By distribution channel, 2019-2028 (USD Million)
TABLE 239 russia NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 240 russia Spinal Cord Stimulation (SCS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 241 russia External Peripheral Nerve Stimulation in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 242 russia Deep Brain Stimulators (DBS) in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 243 russia Transcutaneous Electrical Nerve Stimulation (TENS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 244 russia NEUROPATHIC PAIN MARKET, By PRODUCT TYPE, 2019-2028 (USD Million)
TABLE 245 russia NEUROPATHIC PAIN MARKET, By PROcedure, 2019-2028 (USD Million)
TABLE 246 russia NEUROPATHIC PAIN MARKET, By technology, 2019-2028 (USD Million)
TABLE 247 russia NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 248 russia Stationary in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 249 russia portable in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 250 russia NEUROPATHIC PAIN MARKET, By Mode of purchase, 2019-2028 (USD Million)
TABLE 251 russia NEUROPATHIC PAIN MARKET, By pain type, 2019-2028 (USD Million)
TABLE 252 russia NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 253 russia SPINAL STENOSIS IN NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 254 russia Chemotherapy-Induced Peripheral Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 255 russia Diabetic Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 256 russia NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)
TABLE 257 russia hospitals in NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)
TABLE 258 russia NEUROPATHIC PAIN MARKET, By distribution channel, 2019-2028 (USD Million)
TABLE 259 spain NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 260 spain Spinal Cord Stimulation (SCS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 261 spain External Peripheral Nerve Stimulation in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 262 spain Deep Brain Stimulators (DBS) in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 263 spain Transcutaneous Electrical Nerve Stimulation (TENS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 264 spain NEUROPATHIC PAIN MARKET, By PRODUCT TYPE, 2019-2028 (USD Million)
TABLE 265 spain NEUROPATHIC PAIN MARKET, By PROcedure, 2019-2028 (USD Million)
TABLE 266 spain NEUROPATHIC PAIN MARKET, By technology, 2019-2028 (USD Million)
TABLE 267 spain NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 268 spain Stationary in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 269 spain portable in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 270 spain NEUROPATHIC PAIN MARKET, By Mode of purchase, 2019-2028 (USD Million)
TABLE 271 spain NEUROPATHIC PAIN MARKET, By pain type, 2019-2028 (USD Million)
TABLE 272 spain NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 273 spain SPINAL STENOSIS IN NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 274 spain Chemotherapy-Induced Peripheral Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 275 spain Diabetic Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 276 russia NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)
TABLE 277 spain hospitals in NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)
TABLE 278 spain NEUROPATHIC PAIN MARKET, By distribution channel, 2019-2028 (USD Million)
TABLE 279 Netherlands NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 280 Netherlands Spinal Cord Stimulation (SCS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 281 Netherlands External Peripheral Nerve Stimulation in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 282 Netherlands Deep Brain Stimulators (DBS) in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 283 Netherlands Transcutaneous Electrical Nerve Stimulation (TENS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 284 Netherlands NEUROPATHIC PAIN MARKET, By PRODUCT TYPE, 2019-2028 (USD Million)
TABLE 285 Netherlands NEUROPATHIC PAIN MARKET, By PROcedure, 2019-2028 (USD Million)
TABLE 286 Netherlands NEUROPATHIC PAIN MARKET, By technology, 2019-2028 (USD Million)
TABLE 287 Netherlands NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 288 Netherlands Stationary in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 289 Netherlands portable in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 290 Netherlands NEUROPATHIC PAIN MARKET, By Mode of purchase, 2019-2028 (USD Million)
TABLE 291 Netherlands NEUROPATHIC PAIN MARKET, By pain type, 2019-2028 (USD Million)
TABLE 292 Netherlands NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 293 Netherlands SPINAL STENOSIS IN NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 294 Netherlands Chemotherapy-Induced Peripheral Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 295 Netherlands Diabetic Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 296 Netherlands NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)
TABLE 297 Netherlands hospitals in NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)
TABLE 298 Netherlands NEUROPATHIC PAIN MARKET, By distribution channel, 2019-2028 (USD Million)
TABLE 299 turkey NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 300 turkey Spinal Cord Stimulation (SCS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 301 turkey External Peripheral Nerve Stimulation in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 302 turkey Deep Brain Stimulators (DBS) in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 303 turkey Transcutaneous Electrical Nerve Stimulation (TENS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 304 turkey NEUROPATHIC PAIN MARKET, By PRODUCT TYPE, 2019-2028 (USD Million)
TABLE 305 turkey NEUROPATHIC PAIN MARKET, By PROcedure, 2019-2028 (USD Million)
TABLE 306 turkey NEUROPATHIC PAIN MARKET, By technology, 2019-2028 (USD Million)
TABLE 307 turkey NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 308 turkey Stationary in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 309 turkey portable in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 310 turkey NEUROPATHIC PAIN MARKET, By Mode of purchase, 2019-2028 (USD Million)
TABLE 311 turkey NEUROPATHIC PAIN MARKET, By pain type, 2019-2028 (USD Million)
TABLE 312 turkey NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 313 turkey SPINAL STENOSIS IN NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 314 turkey Chemotherapy-Induced Peripheral Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 315 turkey Diabetic Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 316 turkey NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)
TABLE 317 turkey hospitals in NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)
TABLE 318 turkey NEUROPATHIC PAIN MARKET, By distribution channel, 2019-2028 (USD Million)
TABLE 319 Switzerland NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 320 Switzerland Spinal Cord Stimulation (SCS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 321 Switzerland External Peripheral Nerve Stimulation in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 322 Switzerland Deep Brain Stimulators (DBS) in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 323 Switzerland Transcutaneous Electrical Nerve Stimulation (TENS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 324 Switzerland NEUROPATHIC PAIN MARKET, By PRODUCT TYPE, 2019-2028 (USD Million)
TABLE 325 Switzerland NEUROPATHIC PAIN MARKET, By PROcedure, 2019-2028 (USD Million)
TABLE 326 Switzerland NEUROPATHIC PAIN MARKET, By technology, 2019-2028 (USD Million)
TABLE 327 Switzerland NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 328 Switzerland Stationary in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 329 Switzerland portable in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 330 Switzerland NEUROPATHIC PAIN MARKET, By Mode of purchase, 2019-2028 (USD Million)
TABLE 331 Switzerland NEUROPATHIC PAIN MARKET, By pain type, 2019-2028 (USD Million)
TABLE 332 Switzerland NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 333 Switzerland SPINAL STENOSIS IN NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 334 Switzerland Chemotherapy-Induced Peripheral Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 335 Switzerland Diabetic Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 336 Switzerland NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)
TABLE 337 Switzerland hospitals in NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)
TABLE 338 Switzerland NEUROPATHIC PAIN MARKET, By distribution channel, 2019-2028 (USD Million)
TABLE 339 Rest of Europe NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 340 Asia-Pacific NEUROPATHIC PAIN MARKET, By Region, 2019-2028 (USD Million)
TABLE 341 ASIA-PACIFIC NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 342 ASIA-PACIFIC Spinal Cord Stimulation (SCS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 343 ASIA-PACIFIC External Peripheral Nerve Stimulation in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 344 ASIA-PACIFIC Deep Brain Stimulators (DBS) in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 345 ASIA-PACIFIC Transcutaneous Electrical Nerve Stimulation (TENS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 346 ASIA-PACIFIC NEUROPATHIC PAIN MARKET, By PRODUCT TYPE, 2019-2028 (USD Million)
TABLE 347 ASIA-PACIFIC NEUROPATHIC PAIN MARKET, By PROcedure, 2019-2028 (USD Million)
TABLE 348 ASIA-PACIFIC NEUROPATHIC PAIN MARKET, By technology, 2019-2028 (USD Million)
TABLE 349 ASIA-PACIFIC NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 350 ASIA-PACIFIC Stationary in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 351 ASIA-PACIFIC portable in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 352 ASIA-PACIFIC NEUROPATHIC PAIN MARKET, By Mode of purchase, 2019-2028 (USD Million)
TABLE 353 ASIA-PACIFIC NEUROPATHIC PAIN MARKET, By pain type, 2019-2028 (USD Million)
TABLE 354 ASIA-PACIFIC NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 355 ASIA-PACIFIC SPINAL STENOSIS IN NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 356 ASIA-PACIFIC Chemotherapy-Induced Peripheral Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 357 ASIA-PACIFIC Diabetic Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 358 ASIA-PACIFIC NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)
TABLE 359 ASIA-PACIFIC hospitals in NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)
TABLE 360 ASIA-PACIFIC NEUROPATHIC PAIN MARKET, By distribution channel, 2019-2028 (USD Million)
TABLE 361 china NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 362 china Spinal Cord Stimulation (SCS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 363 china External Peripheral Nerve Stimulation in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 364 china Deep Brain Stimulators (DBS) in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 365 china Transcutaneous Electrical Nerve Stimulation (TENS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 366 china NEUROPATHIC PAIN MARKET, By PRODUCT TYPE, 2019-2028 (USD Million)
TABLE 367 china NEUROPATHIC PAIN MARKET, By PROcedure, 2019-2028 (USD Million)
TABLE 368 china NEUROPATHIC PAIN MARKET, By technology, 2019-2028 (USD Million)
TABLE 369 china NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 370 china Stationary in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 371 china portable in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 372 china NEUROPATHIC PAIN MARKET, By Mode of purchase, 2019-2028 (USD Million)
TABLE 373 china NEUROPATHIC PAIN MARKET, By pain type, 2019-2028 (USD Million)
TABLE 374 china NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 375 china SPINAL STENOSIS IN NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 376 china Chemotherapy-Induced Peripheral Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 377 china Diabetic Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 378 china NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)
TABLE 379 china hospitals in NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)
TABLE 380 china NEUROPATHIC PAIN MARKET, By distribution channel, 2019-2028 (USD Million)
TABLE 381 japan NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 382 japan Spinal Cord Stimulation (SCS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 383 japan External Peripheral Nerve Stimulation in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 384 japan Deep Brain Stimulators (DBS) in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 385 japan Transcutaneous Electrical Nerve Stimulation (TENS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 386 japan NEUROPATHIC PAIN MARKET, By PRODUCT TYPE, 2019-2028 (USD Million)
TABLE 387 japan NEUROPATHIC PAIN MARKET, By PROcedure, 2019-2028 (USD Million)
TABLE 388 japan NEUROPATHIC PAIN MARKET, By technology, 2019-2028 (USD Million)
TABLE 389 japan NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 390 japan Stationary in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 391 japan portable in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 392 japan NEUROPATHIC PAIN MARKET, By Mode of purchase, 2019-2028 (USD Million)
TABLE 393 japan NEUROPATHIC PAIN MARKET, By pain type, 2019-2028 (USD Million)
TABLE 394 japan NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 395 japan SPINAL STENOSIS IN NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 396 japan Chemotherapy-Induced Peripheral Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 397 japan Diabetic Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 398 japan NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)
TABLE 399 japan hospitals in NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)
TABLE 400 japan NEUROPATHIC PAIN MARKET, By distribution channel, 2019-2028 (USD Million)
TABLE 401 australia NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 402 australia Spinal Cord Stimulation (SCS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 403 australia External Peripheral Nerve Stimulation in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 404 australia Deep Brain Stimulators (DBS) in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 405 australia Transcutaneous Electrical Nerve Stimulation (TENS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 406 australia NEUROPATHIC PAIN MARKET, By PRODUCT TYPE, 2019-2028 (USD Million)
TABLE 407 australia NEUROPATHIC PAIN MARKET, By PROcedure, 2019-2028 (USD Million)
TABLE 408 australia NEUROPATHIC PAIN MARKET, By technology, 2019-2028 (USD Million)
TABLE 409 australia NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 410 australia Stationary in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 411 australia portable in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 412 australia NEUROPATHIC PAIN MARKET, By Mode of purchase, 2019-2028 (USD Million)
TABLE 413 australia NEUROPATHIC PAIN MARKET, By pain type, 2019-2028 (USD Million)
TABLE 414 australia NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 415 australia SPINAL STENOSIS IN NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 416 australia Chemotherapy-Induced Peripheral Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 417 australia Diabetic Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 418 australia NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)
TABLE 419 australia hospitals in NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)
TABLE 420 australia NEUROPATHIC PAIN MARKET, By distribution channel, 2019-2028 (USD Million)
TABLE 421 india NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 422 india Spinal Cord Stimulation (SCS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 423 india External Peripheral Nerve Stimulation in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 424 india Deep Brain Stimulators (DBS) in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 425 india Transcutaneous Electrical Nerve Stimulation (TENS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 426 india NEUROPATHIC PAIN MARKET, By PRODUCT TYPE, 2019-2028 (USD Million)
TABLE 427 india NEUROPATHIC PAIN MARKET, By PROcedure, 2019-2028 (USD Million)
TABLE 428 india NEUROPATHIC PAIN MARKET, By technology, 2019-2028 (USD Million)
TABLE 429 india NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 430 india Stationary in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 431 india portable in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 432 india NEUROPATHIC PAIN MARKET, By Mode of purchase, 2019-2028 (USD Million)
TABLE 433 india NEUROPATHIC PAIN MARKET, By pain type, 2019-2028 (USD Million)
TABLE 434 india NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 435 india SPINAL STENOSIS IN NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 436 india Chemotherapy-Induced Peripheral Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 437 india Diabetic Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 438 india NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)
TABLE 439 india hospitals in NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)
TABLE 440 india NEUROPATHIC PAIN MARKET, By distribution channel, 2019-2028 (USD Million)
TABLE 441 south korea NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 442 south korea Spinal Cord Stimulation (SCS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 443 south korea External Peripheral Nerve Stimulation in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 444 south korea Deep Brain Stimulators (DBS) in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 445 south korea Transcutaneous Electrical Nerve Stimulation (TENS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 446 south korea NEUROPATHIC PAIN MARKET, By PRODUCT TYPE, 2019-2028 (USD Million)
TABLE 447 south korea NEUROPATHIC PAIN MARKET, By PROcedure, 2019-2028 (USD Million)
TABLE 448 south korea NEUROPATHIC PAIN MARKET, By technology, 2019-2028 (USD Million)
TABLE 449 south korea NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 450 south korea Stationary in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 451 south korea portable in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 452 south korea NEUROPATHIC PAIN MARKET, By Mode of purchase, 2019-2028 (USD Million)
TABLE 453 south korea NEUROPATHIC PAIN MARKET, By pain type, 2019-2028 (USD Million)
TABLE 454 south korea NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 455 south korea SPINAL STENOSIS IN NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 456 south korea Chemotherapy-Induced Peripheral Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 457 south korea Diabetic Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 458 south korea NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)
TABLE 459 south korea hospitals in NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)
TABLE 460 south korea NEUROPATHIC PAIN MARKET, By distribution channel, 2019-2028 (USD Million)
TABLE 461 singapore NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 462 singapore Spinal Cord Stimulation (SCS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 463 singapore External Peripheral Nerve Stimulation in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 464 singapore Deep Brain Stimulators (DBS) in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 465 singapore Transcutaneous Electrical Nerve Stimulation (TENS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 466 singapore NEUROPATHIC PAIN MARKET, By PRODUCT TYPE, 2019-2028 (USD Million)
TABLE 467 singapore NEUROPATHIC PAIN MARKET, By PROcedure, 2019-2028 (USD Million)
TABLE 468 singapore NEUROPATHIC PAIN MARKET, By technology, 2019-2028 (USD Million)
TABLE 469 singapore NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 470 singapore Stationary in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 471 singapore portable in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 472 singapore NEUROPATHIC PAIN MARKET, By Mode of purchase, 2019-2028 (USD Million)
TABLE 473 singapore NEUROPATHIC PAIN MARKET, By pain type, 2019-2028 (USD Million)
TABLE 474 singapore NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 475 singapore SPINAL STENOSIS IN NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 476 singapore Chemotherapy-Induced Peripheral Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 477 singapore Diabetic Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 478 singapore NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)
TABLE 479 singapore hospitals in NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)
TABLE 480 singapore NEUROPATHIC PAIN MARKET, By distribution channel, 2019-2028 (USD Million)
TABLE 481 malaysia NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 482 malaysia Spinal Cord Stimulation (SCS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 483 malaysia External Peripheral Nerve Stimulation in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 484 malaysia Deep Brain Stimulators (DBS) in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 485 malaysia Transcutaneous Electrical Nerve Stimulation (TENS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 486 malaysia NEUROPATHIC PAIN MARKET, By PRODUCT TYPE, 2019-2028 (USD Million)
TABLE 487 malaysia NEUROPATHIC PAIN MARKET, By PROcedure, 2019-2028 (USD Million)
TABLE 488 malaysia NEUROPATHIC PAIN MARKET, By technology, 2019-2028 (USD Million)
TABLE 489 malaysia NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 490 malaysia Stationary in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 491 malaysia portable in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 492 malaysia NEUROPATHIC PAIN MARKET, By Mode of purchase, 2019-2028 (USD Million)
TABLE 493 malaysia NEUROPATHIC PAIN MARKET, By pain type, 2019-2028 (USD Million)
TABLE 494 malaysia NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 495 malaysia SPINAL STENOSIS IN NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 496 malaysia Chemotherapy-Induced Peripheral Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 497 malaysia Diabetic Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 498 malaysia NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)
TABLE 499 malaysia hospitals in NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)
TABLE 500 malaysia NEUROPATHIC PAIN MARKET, By distribution channel, 2019-2028 (USD Million)
TABLE 501 thailand NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 502 thailand Spinal Cord Stimulation (SCS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 503 thailand External Peripheral Nerve Stimulation in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 504 thailand Deep Brain Stimulators (DBS) in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 505 thailand Transcutaneous Electrical Nerve Stimulation (TENS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 506 thailand NEUROPATHIC PAIN MARKET, By PRODUCT TYPE, 2019-2028 (USD Million)
TABLE 507 thailand NEUROPATHIC PAIN MARKET, By PROcedure, 2019-2028 (USD Million)
TABLE 508 thailand NEUROPATHIC PAIN MARKET, By technology, 2019-2028 (USD Million)
TABLE 509 thailand NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 510 thailand Stationary in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 511 thailand portable in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 512 thailand NEUROPATHIC PAIN MARKET, By Mode of purchase, 2019-2028 (USD Million)
TABLE 513 thailand NEUROPATHIC PAIN MARKET, By pain type, 2019-2028 (USD Million)
TABLE 514 thailand NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 515 thailand SPINAL STENOSIS IN NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 516 thailand Chemotherapy-Induced Peripheral Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 517 thailand Diabetic Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 518 thailand NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)
TABLE 519 thailand hospitals in NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)
TABLE 520 thailand NEUROPATHIC PAIN MARKET, By distribution channel, 2019-2028 (USD Million)
TABLE 521 indonesia NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 522 indonesia Spinal Cord Stimulation (SCS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 523 indonesia External Peripheral Nerve Stimulation in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 524 indonesia Deep Brain Stimulators (DBS) in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 525 indonesia Transcutaneous Electrical Nerve Stimulation (TENS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 526 indonesia NEUROPATHIC PAIN MARKET, By PRODUCT TYPE, 2019-2028 (USD Million)
TABLE 527 indonesia NEUROPATHIC PAIN MARKET, By PROcedure, 2019-2028 (USD Million)
TABLE 528 indonesia NEUROPATHIC PAIN MARKET, By technology, 2019-2028 (USD Million)
TABLE 529 indonesia NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 530 indonesia Stationary in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 531 indonesia portable in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 532 indonesia NEUROPATHIC PAIN MARKET, By Mode of purchase, 2019-2028 (USD Million)
TABLE 533 indonesia NEUROPATHIC PAIN MARKET, By pain type, 2019-2028 (USD Million)
TABLE 534 indonesia NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 535 indonesia SPINAL STENOSIS IN NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 536 indonesia Chemotherapy-Induced Peripheral Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 537 indonesia Diabetic Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 538 indonesia NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)
TABLE 539 indonesia hospitals in NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)
TABLE 540 indonesia NEUROPATHIC PAIN MARKET, By distribution channel, 2019-2028 (USD Million)
TABLE 541 philippines NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 542 philippines Spinal Cord Stimulation (SCS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 543 philippines External Peripheral Nerve Stimulation in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 544 philippines Deep Brain Stimulators (DBS) in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 545 philippines Transcutaneous Electrical Nerve Stimulation (TENS) Devices in NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 546 philippines NEUROPATHIC PAIN MARKET, By PRODUCT TYPE, 2019-2028 (USD Million)
TABLE 547 philippines NEUROPATHIC PAIN MARKET, By PROcedure, 2019-2028 (USD Million)
TABLE 548 philippines NEUROPATHIC PAIN MARKET, By technology, 2019-2028 (USD Million)
TABLE 549 philippines NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 550 philippines Stationary in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 551 philippines portable in NEUROPATHIC PAIN MARKET, By Modality, 2019-2028 (USD Million)
TABLE 552 philippines NEUROPATHIC PAIN MARKET, By Mode of purchase, 2019-2028 (USD Million)
TABLE 553 philippines NEUROPATHIC PAIN MARKET, By pain type, 2019-2028 (USD Million)
TABLE 554 philippines NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 555 philippines SPINAL STENOSIS IN NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 556 philippines Chemotherapy-Induced Peripheral Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 557 philippines Diabetic Neuropathy in NEUROPATHIC PAIN MARKET, By INDICATION, 2019-2028 (USD Million)
TABLE 558 philippines NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)
TABLE 559 philippines hospitals in NEUROPATHIC PAIN MARKET, By end user, 2019-2028 (USD Million)
TABLE 560 philippines NEUROPATHIC PAIN MARKET, By distribution channel, 2019-2028 (USD Million)
TABLE 561 Rest of Asia-Pacific NEUROPATHIC PAIN MARKET, By type, 2019-2028 (USD Million)
TABLE 562 Middle East & Africa Neuropathic pain Market, By Region, 2019-2028 (USD Million)
TABLE 563 Middle East And Africa Neuropathic Pain Market, By Type, 2019-2028 (USD Million)
TABLE 564 Middle East And Africa Spinal Cord Stimulation (SCS) Devices in Neuropathic Pain Market, By Type, 2019-2028 (USD Million)
TABLE 565 Middle East And Africa External Peripheral Nerve Stimulationin Neuropathic Pain Market, By Type, 2019-2028 (USD Million)
TABLE 566 Middle East And Africa Deep Brain Stimulators (DBS) in Neuropathic Pain Market, By Type, 2019-2028 (USD Million)
TABLE 567 Middle East And Africa Transcutaneous Electrical Nerve Stimulation (TENS) Devices in Neuropathic Pain Market, By Type, 2019-2028 (USD Million)
TABLE 568 Middle East And Africa Neuropathic Pain Market, By Product Type, 2019-2028 (USD Million)
TABLE 569 Middle East And Africa Neuropathic Pain Device Market, By Procedure, 2019-2028 (USD Million)
TABLE 570 Middle East And Africa Neuropathic Pain Market, By Technology, 2019-2028 (USD Million)
TABLE 571 Middle East And Africa Neuropathic Pain Market, By Modality, 2019-2028 (USD Million)
TABLE 572 Middle East And Africa Stationary in Neuropathic Pain Market, By Modality, 2019-2028 (USD Million)
TABLE 573 Middle East And Africa Portable in Neuropathic Pain Market, By Modality, 2019-2028 (USD Million)
TABLE 574 Middle East And Africa Neuropathic Pain Market, By Mode of Purchase, 2019-2028 (USD Million)
TABLE 575 Middle East And Africa Neuropathic Pain Market, By Pain Type, 2019-2028 (USD Million)
TABLE 576 Middle East And Africa Neuropathic Pain Market, By Indication, 2019-2028 (USD Million)
TABLE 577 Middle East And Africa Spinal Stenosis in Neuropathic Pain Market, By Indication, 2019-2028 (USD Million)
TABLE 578 Middle East And Africa Chemotherapy-Induced Peripheral Neuropathy in Neuropathic Pain Market, By Indication, 2019-2028 (USD Million)
TABLE 579 Middle East And Africa Diabetic Neuropathy in Neuropathic Pain Market, By Indication, 2019-2028 (USD Million)
TABLE 580 Middle East And Africa Neuropathic Pain Market, By End User, 2019-2028 (USD Million)
TABLE 581 Middle East And Africa Neuropathic Pain Market, By End User, 2019-2028 (USD Million)
TABLE 582 Middle East And Africa Neuropathic Pain Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 583 South Africa Neuropathic Pain Market, By Type, 2019-2028 (USD Million)
TABLE 584 South Africa Spinal Cord Stimulation (SCS) Devices in Neuropathic Pain Market, By Type, 2019-2028 (USD Million)
TABLE 585 South Africa External Peripheral Nerve Stimulationin Neuropathic Pain Market, By Type, 2019-2028 (USD Million)
TABLE 586 South Africa Deep Brain Stimulators (DBS) in Neuropathic Pain Market, By Type, 2019-2028 (USD Million)
TABLE 587 South Africa Transcutaneous Electrical Nerve Stimulation (TENS) Devices in Neuropathic Pain Market, By Type, 2019-2028 (USD Million)
TABLE 588 South Africa Neuropathic Pain Market, By Product Type, 2019-2028 (USD Million)
TABLE 589 South Africa Neuropathic Pain Device Market, By Procedure, 2019-2028 (USD Million)
TABLE 590 South Africa Neuropathic Pain Market, By Technology, 2019-2028 (USD Million)
TABLE 591 South Africa Neuropathic Pain Market, By Modality, 2019-2028 (USD Million)
TABLE 592 South Africa Stationary in Neuropathic Pain Market, By Modality, 2019-2028 (USD Million)
TABLE 593 South Africa Portable in Neuropathic Pain Market, By Modality, 2019-2028 (USD Million)
TABLE 594 South Africa Neuropathic Pain Market, By Mode of Purchase, 2019-2028 (USD Million)
TABLE 595 South Africa Neuropathic Pain Market, By Pain Type, 2019-2028 (USD Million)
TABLE 596 South Africa Neuropathic Pain Market, By Indication, 2019-2028 (USD Million)
TABLE 597 South Africa Spinal Stenosis in Neuropathic Pain Market, By Indication, 2019-2028 (USD Million)
TABLE 598 South Africa Chemotherapy-Induced Peripheral Neuropathy in Neuropathic Pain Market, By Indication, 2019-2028 (USD Million)
TABLE 599 South Africa Diabetic Neuropathy in Neuropathic Pain Market, By Indication, 2019-2028 (USD Million)
TABLE 600 South Africa Neuropathic Pain Market, By End User, 2019-2028 (USD Million)
TABLE 601 South Africa Hospitals in Neuropathic Pain Market, By End User, 2019-2028 (USD Million)
TABLE 602 South Africa Neuropathic Pain Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 603 Saudi Arabia Neuropathic Pain Market, By Type, 2019-2028 (USD Million)
TABLE 604 Saudi Arabia Spinal Cord Stimulation (SCS) Devices in Neuropathic Pain Market, By Type, 2019-2028 (USD Million)
TABLE 605 Saudi Arabia External Peripheral Nerve Stimulationin Neuropathic Pain Market, By Type, 2019-2028 (USD Million)
TABLE 606 Saudi Arabia Deep Brain Stimulators (DBS) in Neuropathic Pain Market, By Type, 2019-2028 (USD Million)
TABLE 607 Saudi Arabia Transcutaneous Electrical Nerve Stimulation (TENS) Devices in Neuropathic Pain Market, By Type, 2019-2028 (USD Million)
TABLE 608 Saudi Arabia Neuropathic Pain Market, By Product Type, 2019-2028 (USD Million)
TABLE 609 Saudi Arabia Neuropathic Pain Device Market, By Procedure, 2019-2028 (USD Million)
TABLE 610 Saudi Arabia Neuropathic Pain Market, By Technology, 2019-2028 (USD Million)
TABLE 611 Saudi Arabia Neuropathic Pain Market, By Modality, 2019-2028 (USD Million)
TABLE 612 Saudi Arabia Stationary in Neuropathic Pain Market, By Modality, 2019-2028 (USD Million)
TABLE 613 Saudi Arabia Portable in Neuropathic Pain Market, By Modality, 2019-2028 (USD Million)
TABLE 614 Saudi Arabia Neuropathic Pain Market, By Mode of Purchase, 2019-2028 (USD Million)
TABLE 615 Saudi Arabia Neuropathic Pain Market, By Pain Type, 2019-2028 (USD Million)
TABLE 616 Saudi Arabia Neuropathic Pain Market, By Indication, 2019-2028 (USD Million)
TABLE 617 Saudi Arabia Spinal Stenosis in Neuropathic Pain Market, By Indication, 2019-2028 (USD Million)
TABLE 618 Saudi Arabia Chemotherapy-Induced Peripheral Neuropathy in Neuropathic Pain Market, By Indication, 2019-2028 (USD Million)
TABLE 619 Saudi Arabia Diabetic Neuropathy in Neuropathic Pain Market, By Indication, 2019-2028 (USD Million)
TABLE 620 Saudi Arabia Neuropathic Pain Market, By End User, 2019-2028 (USD Million)
TABLE 621 Saudi Arabia Hospitals in Neuropathic Pain Market, By End User, 2019-2028 (USD Million)
TABLE 622 Saudi Arabia Neuropathic Pain Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 623 UAE Neuropathic Pain Market, By Type, 2019-2028 (USD Million)
TABLE 624 UAE Spinal Cord Stimulation (SCS) Devices in Neuropathic Pain Market, By Type, 2019-2028 (USD Million)
TABLE 625 UAE External Peripheral Nerve Stimulationin Neuropathic Pain Market, By Type, 2019-2028 (USD Million)
TABLE 626 UAE Deep Brain Stimulators (DBS) in Neuropathic Pain Market, By Type, 2019-2028 (USD Million)
TABLE 627 UAE Transcutaneous Electrical Nerve Stimulation (TENS) Devices in Neuropathic Pain Market, By Type, 2019-2028 (USD Million)
TABLE 628 UAE Neuropathic Pain Market, By Product Type, 2019-2028 (USD Million)
TABLE 629 UAE Neuropathic Pain Device Market, By Procedure, 2019-2028 (USD Million)
TABLE 630 UAE Neuropathic Pain Market, By Technology, 2019-2028 (USD Million)
TABLE 631 UAE Neuropathic Pain Market, By Modality, 2019-2028 (USD Million)
TABLE 632 UAE Stationary in Neuropathic Pain Market, By Modality, 2019-2028 (USD Million)
TABLE 633 UAE Portable in Neuropathic Pain Market, By Modality, 2019-2028 (USD Million)
TABLE 634 UAE Neuropathic Pain Market, By Mode of Purchase, 2019-2028 (USD Million)
TABLE 635 UAE Neuropathic Pain Market, By Pain Type, 2019-2028 (USD Million)
TABLE 636 UAE Neuropathic Pain Market, By Indication, 2019-2028 (USD Million)
TABLE 637 UAE Spinal Stenosis in Neuropathic Pain Market, By Indication, 2019-2028 (USD Million)
TABLE 638 UAE Chemotherapy-Induced Peripheral Neuropathy in Neuropathic Pain Market, By Indication, 2019-2028 (USD Million)
TABLE 639 UAE Diabetic Neuropathy in Neuropathic Pain Market, By Indication, 2019-2028 (USD Million)
TABLE 640 UAE Neuropathic Pain Market, By End User, 2019-2028 (USD Million)
TABLE 641 UAE Hospitals in Neuropathic Pain Market, By End User, 2019-2028 (USD Million)
TABLE 642 UAE Neuropathic Pain Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 643 ISRAEL Neuropathic Pain Market, By Type, 2019-2028 (USD Million)
TABLE 644 ISRAEL Spinal Cord Stimulation (SCS) Devices in Neuropathic Pain Market, By Type, 2019-2028 (USD Million)
TABLE 645 ISRAEL External Peripheral Nerve Stimulationin Neuropathic Pain Market, By Type, 2019-2028 (USD Million)
TABLE 646 ISRAEL Deep Brain Stimulators (DBS) in Neuropathic Pain Market, By Type, 2019-2028 (USD Million)
TABLE 647 iSRAEL Transcutaneous Electrical Nerve Stimulation (TENS) Devices in Neuropathic Pain Market, By Type, 2019-2028 (USD Million)
TABLE 648 ISRAEL Neuropathic Pain Market, By Product Type, 2019-2028 (USD Million)
TABLE 649 ISRAEL Neuropathic Pain Device Market, By Procedure, 2019-2028 (USD Million)
TABLE 650 ISRAEL Neuropathic Pain Market, By Technology, 2019-2028 (USD Million)
TABLE 651 ISRAEL Neuropathic Pain Market, By Modality, 2019-2028 (USD Million)
TABLE 652 ISRAEL Stationary in Neuropathic Pain Market, By Modality, 2019-2028 (USD Million)
TABLE 653 ISRAEL Portable in Neuropathic Pain Market, By Modality, 2019-2028 (USD Million)
TABLE 654 ISRAEL Neuropathic Pain Market, By Mode of Purchase, 2019-2028 (USD Million)
TABLE 655 ISRAEL Neuropathic Pain Market, By Pain Type, 2019-2028 (USD Million)
TABLE 656 ISRAEL Neuropathic Pain Market, By Indication, 2019-2028 (USD Million)
TABLE 657 ISRAEL Spinal Stenosis in Neuropathic Pain Market, By Indication, 2019-2028 (USD Million)
TABLE 658 ISRAEL Chemotherapy-Induced Peripheral Neuropathy in Neuropathic Pain Market, By Indication, 2019-2028 (USD Million)
TABLE 659 ISRAEL Diabetic Neuropathy in Neuropathic Pain Market, By Indication, 2019-2028 (USD Million)
TABLE 660 ISRAEL Neuropathic Pain Market, By End User, 2019-2028 (USD Million)
TABLE 661 ISRAEL Hospitals in Neuropathic Pain Market, By End User, 2019-2028 (USD Million)
TABLE 662 ISRAEL Neuropathic Pain Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 663 EGYPT Neuropathic Pain Market, By Type, 2019-2028 (USD Million)
TABLE 664 EGYPT Spinal Cord Stimulation (SCS) Devices in Neuropathic Pain Market, By Type, 2019-2028 (USD Million)
TABLE 665 EGYPT External Peripheral Nerve Stimulationin Neuropathic Pain Market, By Type, 2019-2028 (USD Million)
TABLE 666 EGYPT Deep Brain Stimulators (DBS) in Neuropathic Pain Market, By Type, 2019-2028 (USD Million)
TABLE 667 EGYPT Transcutaneous Electrical Nerve Stimulation (TENS) Devices in Neuropathic Pain Market, By Type, 2019-2028 (USD Million)
TABLE 668 EGYPT Neuropathic Pain Market, By Product Type, 2019-2028 (USD Million)
TABLE 669 EGYPT Neuropathic Pain Device Market, By Procedure, 2019-2028 (USD Million)
TABLE 670 EGYPT Neuropathic Pain Market, By Technology, 2019-2028 (USD Million)
TABLE 671 EGYPT Neuropathic Pain Market, By Modality, 2019-2028 (USD Million)
TABLE 672 EGYPT Stationary in Neuropathic Pain Market, By Modality, 2019-2028 (USD Million)
TABLE 673 EGYPT Portable in Neuropathic Pain Market, By Modality, 2019-2028 (USD Million)
TABLE 674 EGYPT Neuropathic Pain Market, By Mode of Purchase, 2019-2028 (USD Million)
TABLE 675 EGYPT Neuropathic Pain Market, By Pain Type, 2019-2028 (USD Million)
TABLE 676 EGYPT Neuropathic Pain Market, By Indication, 2019-2028 (USD Million)
TABLE 677 EGYPT Spinal Stenosis in Neuropathic Pain Market, By Indication, 2019-2028 (USD Million)
TABLE 678 EGYPT Chemotherapy-Induced Peripheral Neuropathy in Neuropathic Pain Market, By Indication, 2019-2028 (USD Million)
TABLE 679 EGYPT Diabetic Neuropathy in Neuropathic Pain Market, By Indication, 2019-2028 (USD Million)
TABLE 680 EGYPT Neuropathic Pain Market, By End User, 2019-2028 (USD Million)
TABLE 681 EGYPT Hospitals in Neuropathic Pain Market, By End User, 2019-2028 (USD Million)
TABLE 682 EGYPT Neuropathic Pain Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 683 EGYPT Neuropathic Pain Market, By Type, 2019-2028 (USD Million)
TABLE 684 SOUTH AMERICA Neuropathic pain Market, By Region, 2019-2028 (USD Million)
TABLE 685 SOUTH AMERICA Neuropathic Pain Market, By Type, 2019-2028 (USD Million)
TABLE 686 SOUTH AMERICA Spinal Cord Stimulation (SCS) Devices in Neuropathic Pain Market, By Type, 2019-2028 (USD Million)
TABLE 687 SOUTH AMERICA External Peripheral Nerve Stimulationin Neuropathic Pain Market, By Type, 2019-2028 (USD Million)
TABLE 688 SOUTH AMERICA Deep Brain Stimulators (DBS) in Neuropathic Pain Market, By Type, 2019-2028 (USD Million)
TABLE 689 SOUTH AMERICA Transcutaneous Electrical Nerve Stimulation (TENS) Devices in Neuropathic Pain Market, By Type, 2019-2028 (USD Million)
TABLE 690 SOUTH AMERICA Neuropathic Pain Market, By Product Type, 2019-2028 (USD Million)
TABLE 691 SOUTH AMERICA Neuropathic Pain Device Market, By Procedure, 2019-2028 (USD Million)
TABLE 692 SOUTH AMERICA Neuropathic Pain Market, By Technology, 2019-2028 (USD Million)
TABLE 693 SOUTH AMERICA Neuropathic Pain Market, By Modality, 2019-2028 (USD Million)
TABLE 694 SOUTH AMERICA Stationary in Neuropathic Pain Market, By Modality, 2019-2028 (USD Million)
TABLE 695 SOUTH AMERICA Portable in Neuropathic Pain Market, By Modality, 2019-2028 (USD Million)
TABLE 696 SOUTH AMERICA Neuropathic Pain Market, By Mode of Purchase, 2019-2028 (USD Million)
TABLE 697 SOUTH AMERICA Neuropathic Pain Market, By Pain Type, 2019-2028 (USD Million)
TABLE 698 SOUTH AMERICA Neuropathic Pain Market, By Indication, 2019-2028 (USD Million)
TABLE 699 SOUTH AMERICA Spinal Stenosis in Neuropathic Pain Market, By Indication, 2019-2028 (USD Million)
TABLE 700 SOUTH AMERICA Chemotherapy-Induced Peripheral Neuropathy in Neuropathic Pain Market, By Indication, 2019-2028 (USD Million)
TABLE 701 SOUTH AMERICA Diabetic Neuropathy in Neuropathic Pain Market, By Indication, 2019-2028 (USD Million)
TABLE 702 SOUTH AMERICA Neuropathic Pain Market, By End User, 2019-2028 (USD Million)
TABLE 703 SOUTH AMERICA Neuropathic Pain Market, By End User, 2019-2028 (USD Million)
TABLE 704 SOUTH AMERICA Neuropathic Pain Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 705 BRAZIL Neuropathic Pain Market, By Type, 2019-2028 (USD Million)
TABLE 706 BRAZIL Spinal Cord Stimulation (SCS) Devices in Neuropathic Pain Market, By Type, 2019-2028 (USD Million)
TABLE 707 BRAZIL External Peripheral Nerve Stimulationin Neuropathic Pain Market, By Type, 2019-2028 (USD Million)
TABLE 708 BRAZIL Deep Brain Stimulators (DBS) in Neuropathic Pain Market, By Type, 2019-2028 (USD Million)
TABLE 709 BRAZIL Transcutaneous Electrical Nerve Stimulation (TENS) Devices in Neuropathic Pain Market, By Type, 2019-2028 (USD Million)
TABLE 710 BRAZIL Neuropathic Pain Market, By Product Type, 2019-2028 (USD Million)
TABLE 711 BRAZIL Neuropathic Pain Device Market, By Procedure, 2019-2028 (USD Million)
TABLE 712 BRAZIL Neuropathic Pain Market, By Technology, 2019-2028 (USD Million)
TABLE 713 BRAZIL Neuropathic Pain Market, By Modality, 2019-2028 (USD Million)
TABLE 714 BRAZIL Stationary in Neuropathic Pain Market, By Modality, 2019-2028 (USD Million)
TABLE 715 BRAZIL Portable in Neuropathic Pain Market, By Modality, 2019-2028 (USD Million)
TABLE 716 BRAZIL Neuropathic Pain Market, By Mode of Purchase, 2019-2028 (USD Million)
TABLE 717 BRAZIL Neuropathic Pain Market, By Pain Type, 2019-2028 (USD Million)
TABLE 718 BRAZIL Neuropathic Pain Market, By Indication, 2019-2028 (USD Million)
TABLE 719 BRAZIL Spinal Stenosis in Neuropathic Pain Market, By Indication, 2019-2028 (USD Million)
TABLE 720 BRAZIL Chemotherapy-Induced Peripheral Neuropathy in Neuropathic Pain Market, By Indication, 2019-2028 (USD Million)
TABLE 721 BRAZIL Diabetic Neuropathy in Neuropathic Pain Market, By Indication, 2019-2028 (USD Million)
TABLE 722 BRAZIL Neuropathic Pain Market, By End User, 2019-2028 (USD Million)
TABLE 723 BRAZIL Hospitals in Neuropathic Pain Market, By End User, 2019-2028 (USD Million)
TABLE 724 BRAZIL Neuropathic Pain Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 725 argentina Neuropathic Pain Market, By Type, 2019-2028 (USD Million)
TABLE 726 ARGENTINA Spinal Cord Stimulation (SCS) Devices in Neuropathic Pain Market, By Type, 2019-2028 (USD Million)
TABLE 727 ARGENTINA External Peripheral Nerve Stimulationin Neuropathic Pain Market, By Type, 2019-2028 (USD Million)
TABLE 728 ARGENTINA Deep Brain Stimulators (DBS) in Neuropathic Pain Market, By Type, 2019-2028 (USD Million)
TABLE 729 ARGENTINA Transcutaneous Electrical Nerve Stimulation (TENS) Devices in Neuropathic Pain Market, By Type, 2019-2028 (USD Million)
TABLE 730 ARGENTINA Neuropathic Pain Market, By Product Type, 2019-2028 (USD Million)
TABLE 731 ARGENTINA Neuropathic Pain Device Market, By Procedure, 2019-2028 (USD Million)
TABLE 732 ARGENTINA Neuropathic Pain Market, By Technology, 2019-2028 (USD Million)
TABLE 733 ARGENTINA Neuropathic Pain Market, By Modality, 2019-2028 (USD Million)
TABLE 734 ARGENTINA Stationary in Neuropathic Pain Market, By Modality, 2019-2028 (USD Million)
TABLE 735 ARGENTINA Portable in Neuropathic Pain Market, By Modality, 2019-2028 (USD Million)
TABLE 736 ARGENTINA Neuropathic Pain Market, By Mode of Purchase, 2019-2028 (USD Million)
TABLE 737 ARGENTINA Neuropathic Pain Market, By Pain Type, 2019-2028 (USD Million)
TABLE 738 ARGENTINA Neuropathic Pain Market, By Indication, 2019-2028 (USD Million)
TABLE 739 ARGENTINA Spinal Stenosis in Neuropathic Pain Market, By Indication, 2019-2028 (USD Million)
TABLE 740 ARGENTINA Chemotherapy-Induced Peripheral Neuropathy in Neuropathic Pain Market, By Indication, 2019-2028 (USD Million)
TABLE 741 ARGENTINA Diabetic Neuropathy in Neuropathic Pain Market, By Indication, 2019-2028 (USD Million)
TABLE 742 ARGENTINA Neuropathic Pain Market, By End User, 2019-2028 (USD Million)
TABLE 743 ARGENTINA Hospitals in Neuropathic Pain Market, By End User, 2019-2028 (USD Million)
TABLE 744 ARGENTINA Neuropathic Pain Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 745 rest of south america Neuropathic Pain Market, By Type, 2019-2028 (USD Million)
Liste des figures
FIGURE 1 Global NEUROPATHIC PAIN MARKET: SEGMENTATION
FIGURE 2 GLOBAL NEUROPATHIC PAIN MARKET: DATA TRIANGULATION
FIGURE 3 global Neuropathic pain Market: DROC ANALYSIS
FIGURE 4 Global Neuropathic pain market: Global VS REGIONAL MARKET ANALYSIS
FIGURE 5 Global Neuropathic pain Market: COMPANY RESEARCH ANALYSIS
FIGURE 6 GLOBAL Neuropathic pain MARKET: MULTIVARIATE MODELLING
FIGURE 7 GLOBAL Neuropathic pain MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 GLOBAL NEUROPATHIC PAIN MARKET: DBMR MARKET POSITION GRID
FIGURE 9 GLOBAL NEUROPATHIC PAIN MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 GLOBAL Neuropathic pain MARKET: MARKET type COVERAGE GRID
FIGURE 11 Global Neuropathic pain market: SEGMENTATION
FIGURE 12 NORTH AMERICA is expected to DOMINATE THE GLOBAL Neuropathic pain market AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 13 GROWING PREVALENCE OF CHRONIC PAIN, NEUROPATHIC CONDITION, AND INCREASING CASES OF DIABETIC NEUROPATHY IS DRIVING THE GLOBAL NEUROPATHIC PAIN MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 14 SPINAL CORD STIMULATION (SCS) DEVICES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL NEUROPATHIC PAIN MARKET IN 2021 & 2028
FIGURE 15 north america is the fastest growing market FOR the Neuropathic pain MANUFACTURERS IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 16 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF GLOBAL NEUROPATHIC PAIN MARKET
FIGURE 17 ESTIMATED CASES OF PERIPHERAL NEUROPATHY IN AMERICAN POPULATION
FIGURE 18 PREVALENCE OF NEUROPATHIC PAIN IN TYPE 1 AND TYPE 2 DIABETES
FIGURE 19 global Neuropathic pain market: BY type, 2020
FIGURE 20 global Neuropathic pain market: BY type, 2020-2028 (USD Million)
FIGURE 21 global Neuropathic pain market: BY type, CAGR (2020-2028)
FIGURE 22 global Neuropathic pain market: BY type, LIFELINE CURVE
FIGURE 23 global Neuropathic pain market: BY product type, 2020
FIGURE 24 global Neuropathic pain market: BY product type, 2020-2028 (USD Million)
FIGURE 25 global Neuropathic pain market: BY product type, CAGR (2020-2028)
FIGURE 26 global Neuropathic pain market: BY product type, LIFELINE CURVE
FIGURE 27 global Neuropathic pain market: BY procedure, 2020
FIGURE 28 global Neuropathic pain market: BY procedure, 2020-2028 (USD Million)
FIGURE 29 global Neuropathic pain market: BY procedure, CAGR (2020-2028)
FIGURE 30 global Neuropathic pain market: BY procedure, LIFELINE CURVE
FIGURE 31 global Neuropathic pain market: BY technology, 2020
FIGURE 32 global Neuropathic pain market: BY technology, 2020-2028 (USD Million)
FIGURE 33 global Neuropathic pain market: BY technology, CAGR (2020-2028)
FIGURE 34 global Neuropathic pain market: BY technology, LIFELINE CURVE
FIGURE 35 global Neuropathic pain market: BY modality, 2020
FIGURE 36 global Neuropathic pain market: BY modality, 2020-2028 (USD Million)
FIGURE 37 global Neuropathic pain market: BY modality, CAGR (2020-2028)
FIGURE 38 global Neuropathic pain market: BY modality, LIFELINE CURVE
FIGURE 39 global Neuropathic pain market: BY mode of purchase, 2020
FIGURE 40 global Neuropathic pain market: BY mode of purchase, 2020-2028 (USD Million)
FIGURE 41 global Neuropathic pain market: BY mode of purchase, CAGR (2020-2028)
FIGURE 42 global Neuropathic pain market: BY mode of purchase, LIFELINE CURVE
FIGURE 43 global Neuropathic pain market: BY pain type, 2020
FIGURE 44 global Neuropathic pain market: BY pain type, 2020-2028 (USD Million)
FIGURE 45 global Neuropathic pain market: BY pain type, CAGR (2020-2028)
FIGURE 46 global Neuropathic pain market: BY pain type, LIFELINE CURVE
FIGURE 47 global Neuropathic pain market: BY indication, 2020
FIGURE 48 global Neuropathic pain market: BY indication, 2020-2028 (USD Million)
FIGURE 49 global Neuropathic pain market: BY indication, CAGR (2020-2028)
FIGURE 50 global Neuropathic pain market: BY indication, LIFELINE CURVE
FIGURE 51 global Neuropathic pain market: BY end user, 2020
FIGURE 52 global Neuropathic pain market: BY end user, 2020-2028 (USD Million)
FIGURE 53 global Neuropathic pain market: BY end user, CAGR (2020-2028)
FIGURE 54 global Neuropathic pain market: BY end user, LIFELINE CURVE
FIGURE 55 global Neuropathic pain market: BY distribution channel, 2020
FIGURE 56 global Neuropathic pain market: BY distribution channel, 2020-2028 (USD Million)
FIGURE 57 global Neuropathic pain market: BY distribution channel, CAGR (2020-2028)
FIGURE 58 global Neuropathic pain market: BY distribution channel, LIFELINE CURVE
FIGURE 59 GLOBAL neuropathic Pain market: SNAPSHOT (2020)
FIGURE 60 GLOBAL neuropathic Pain market: BY COUNTRY (2020)
FIGURE 61 GLOBAL neuropathic Pain market: BY COUNTRY (2021 & 2028)
FIGURE 62 GLOBAL neuropathic Pain market: BY COUNTRY (2020 & 2028)
FIGURE 63 GLOBAL neuropathic Pain market: BY Product & services (2021-2028)
FIGURE 64 North-america Neuropathic Pain MARKET: SNAPSHOT (2020)
FIGURE 65 North-america Neuropathic Pain MARKET: BY COUNTRY (2020)
FIGURE 66 North-america Neuropathic Pain MARKET: BY COUNTRY (2021 & 2028)
FIGURE 67 North-america Neuropathic Pain MARKET: BY COUNTRY (2020 & 2028)
FIGURE 68 North-america Neuropathic Pain MARKET: BY product & Services (2021-2028)
FIGURE 69 Europe Neuropathic Pain MARKET: SNAPSHOT (2020)
FIGURE 70 Europe Neuropathic Pain MARKET: BY COUNTRY (2020)
FIGURE 71 Europe Neuropathic Pain MARKET: BY COUNTRY (2021 & 2028)
FIGURE 72 Europe Neuropathic Pain MARKET: BY COUNTRY (2020 & 2028)
FIGURE 73 Europe Neuropathic Pain MARKET: BY product & Services (2021-2028)
FIGURE 74 Asia-Pacific Neuropathic Pain MARKET: SNAPSHOT (2020)
FIGURE 75 Asia-Pacific Neuropathic Pain MARKET: BY COUNTRY (2020)
FIGURE 76 Asia-Pacific Neuropathic Pain MARKET: BY COUNTRY (2021 & 2028)
FIGURE 77 Asia-Pacific Neuropathic Pain MARKET: BY COUNTRY (2020 & 2028)
FIGURE 78 Asia-Pacific Neuropathic Pain MARKET: BY product & Services (2021-2028)
FIGURE 79 Middle East & Africa NEUROPATHIC PAIN market: SNAPSHOT (2020)
FIGURE 80 Middle East & Africa NEUROPATHIC PAIN market: BY COUNTRY (2020)
FIGURE 81 Middle East & Africa NEUROPATHIC PAIN market: BY COUNTRY (2021 & 2028)
FIGURE 82 Middle East & Africa NEUROPATHIC PAIN market: BY COUNTRY (2020 & 2028)
FIGURE 83 Middle East & Africa NEUROPATHIC PAIN market: BY type (2021-2028)
FIGURE 84 SOUTH AMERICA NEUROPATHIC PAIN market: SNAPSHOT (2020)
FIGURE 85 SOUTH AMERICA NEUROPATHIC PAIN market: BY COUNTRY (2020)
FIGURE 86 SOUTH AMERICA NEUROPATHIC PAIN market: BY COUNTRY (2021 & 2028)
FIGURE 87 SOUTH AMERICA NEUROPATHIC PAIN market: BY COUNTRY (2020 & 2028)
FIGURE 88 SOUTH AMERICA NEUROPATHIC PAIN market: BY type (2021-2028)
FIGURE 89 Global Neuropathic Pain market: company share 2020 (%)
FIGURE 90 North America Neuropathic Pain Market: company share 2020 (%)
FIGURE 91 EUROPE Neuropathic Pain Market: company share 2020 (%)
FIGURE 92 ASIA-PACIFIC Neuropathic Pain Market: company share 2020 (%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.
